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Introduction 
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The complement system: historical perspective 
The complement system is a critical component of the innate immune system.  It 
is composed of multiple proteins, present abundantly in serum, whose early steps are 
activated in a step-wise fashion.  Complement was first described over 100 years ago as 
the heat labile component that “complements” the humoral response by the work of Jules 
Bordet and Paul Ehrlich
1,2
.  The initial observation was that a heat stabile element 
(antibody) plus a heat labile component (complement) would lead to pathogen lysis, 
whereas antibody without complement would not.  It was subsequently elucidated that 
this “factor” was not a single protein, but rather an activation cascade
3
. The complement 
system is highly conserved evolutionarily, being present in species that have only 
primitive immune systems and lack adaptive immunity.  The complement system arose as 
a part of the original innate immune system
4
.   
 
The complement system: function 
The complement system serves as the first line of defense against invading 
pathogens and can be activated in seconds in the blood or hemolymph
5–8
.  Through 
opsonization, it marks pathogens for phagocytosis.  Initiation of the complement system 
also triggers activation of the terminal pathway, which leads to lysis of a target through 
formation of the membrane attack complex.  Next, the complement system serves as a 
bridge (“nature’s adjuvant”) between the innate immune system and the adaptive immune 
system
9
.  The production of anaphylatoxins recruit inflammatory cells such as neutrophils 
and eosinophils to a site of infection.  Signaling through the anaphylatoxin receptors 
" $"
leads to cell activation, production of reactive oxygen species and mast cell and 
neutrophil degranulation.  Additionally, the C3d frament binds to CD19/CD21 on the 
surface of B cells, leading to their activation and stimulation of the adaptive immune 
response
10
.  Deficiency in the central component, C3, has been associated with a poor 
response to vaccinations
11–13
.  Finally, the complement system plays an important role in 
waste disposal as it marks immune complexes and apoptotic cells for elimination by 
phagocytic cells
14
.   
 
The complement system: pathways 
The complement system is composed of three distinct activation pathways: the 
classical, lectin and alternative.  The classical and lectin pathways are triggered via 
specific pattern recognition
15
, whereas the alternative pathway is initiated by a 
spontaneous tickover mechanism
16
.  Though a different trigger initiates each pathway, 
they all converge at the central step of cleavage of C3 (Figure 1.1).   Through careful 
biochemical studies the individual components of each pathway have been identified and 
purified from serum.  
 The classical pathway is initiated when the C1 complex binds to antibody bound 
to antigen (i.e. an immune complex)17.  The C1 complex is composed of C1q, C1r, and 
C1s.  C1q is a protein composed of 6 globular heads each with a collagen-like stalk.  C1r 
and C1s are serine proteases that associate with C1q.  For C1 to be activated, the globular 
heads of C1q first bind to the Fc portion of IgG or IgM in the immune complex. Once in 
the bound conformation, the serine protease C1r autoactivates, and then in turn activates  
" %"
 
 
 
Figure 1.1:  Diagram of the pathways of complement activation. 
 
 
 
 
 
" &"
the serine protease C1s.  C1s then cleaves C4 and C2 to form the classical pathway C3 
convertase, C4b2a.   
In a mechanism analogous to the classical pathway, the lectin pathway is initiated 
when mannose-binding lectin (MBL) recognizes specific carbohydrate moieties on 
pathogen surfaces
15
.  MASP-1 and MASP-2 are the serine proteases that are associated 
with MBL and are akin to C1r and C1s
18
.  Once activated, they also cleave C4 and C2 to 
form the C3 convertase.   
The alternative pathway is initiated by a spontaneous turnover of C3.  This 
“tickover” of C3 is secondary to hydrolysis of the thioester, which induces a 
conformational change in C3 to form C3(H2O)
5.  It is now able to bind to Factor B (FB), 
an inactive serine protease (zymogen).  Once FB has bound to C3(H2O), Factor D (FD) 
cleaves FB to generate Bb and releasing the smaller fragment, Ba.  Bb remains bound to 
C3(H2O) and the complex forms the initiating alternative pathway C3 convertase, 
C3(H2O)Bb.  Once initiated, the alternative pathway acts as an efficient amplification 
loop, generating more and more C3b, which can bind to FB to form more C3 convertases.  
The cleavage products formed by the action of the C3 convertases are C3a and 
C3b.  These activation fragments participate in the two most important effector functions 
of the complement system.  C3a is an anaphylatoxin and chemoattractant.  C3b opsonizes 
target surfaces, which leads to immune adherence followed by phagocytosis of the 
pathogen by macrophages or neutrophils.  Additionally, C3b can form a covalent 
attachment to the C3 convertase to generate the C5 convertases C3b2Bb and C4b2a3b.  
" '"
The C5 convertases cleave C5 to C5a and C5b
19
.  C5a is also a chemoattractant 
and anaphylatoxin.  C5b initiates the terminal pathway activation and, through sequential 
binding of C6, C7, C8 and C9, forms the membrane attack complex (MAC).  The MAC 
contains many molecules of C9 (up to 12), and forms a pore in the cell membrane that 
may lead to osmotic lysis of the target. 
 
The complement system convertases 
The C3 and C5 convertases are bi- or tri-molecular enzyme complexes, 
respectively (Figure 1.2).  As described in the previous section, they are formed by 
proteins of the complement cascade that are activated by proteolytic cleavage.  Activated 
fragments of C4 and C2 form the classical and lectin pathway C3 convertase (C/L C3-
con):  C4b2a.  C4b2a has a higher affinity for C3 and much lower affinity for C5
19,20
.  
C4b2a cleaves C3 through the serine protease domain contained in C2a to C3a and C3b.  
The newly formed C3b can covalently attach to the C4b in the complex, which forms the 
high affinity C5 convertase, C4b2a3b.   
The alternative pathway C3 convertase (AP-C3 con) is initially formed by 
C3(H2O) binding to Factor B.  When bound to C3(H2O),  FB is now susceptible to 
cleavage by FD, which cleaves FB to Ba and Bb21.  Bb remains attached to C3(H2O) and 
is the catalytic serine protease containing domain of the complex.  This convertase also 
cleaves C3 to form C3a and C3b.  The newly formed C3b can either form a new AP C3 
convertase by interacting with FB, or bind to the C3b in the original convertase, forming 
the AP C5 convertase, C3b2Bb.   
" ("
 
 
 
Figure 1.2.  A.  Classical/Lectin pathway convertases. B. Alternative pathway 
convertases.  
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The convertases of both pathways are labile complexes that are susceptible to 
spontaneous decay.  The bonds between the two subunits are not covalent and the two 
will naturally, over time, dissociate.  The half-life of the CP C3 convertase is less than 
five minutes.  The half-life of the AP C3 convertase is even shorter (~90 sec).  However, 
the AP C3 convertase can associate with properdin.  Properdin is a positive regulator of 
the complement cascade.  It increases the half-life of the AP C3 convertase from ~90 sec 
to five to ten min
22
.  Properdin is a protein of 55 kDa, composed of thrombospondin 
repeats.  Each monomer of properdin contains 6 TSR repeats.  Properdin can be found as 
a monomer or as dimers, trimers and tetramers.  In general, the higher order oligomers 
are thought to have more functional significance.  Additionally, properdin has recently 
been shown to be able to function as a platform for assembly of the AP C3 con
23
.  
When C3b is initially generated it can either a) covalently deposit on an activating 
surface (with an ester linkage), such as a bacterial membrane or zymosan (yeast cell well 
particles); b) similarly deposit on a non-activating surface, such as an epithelial cell; or c) 
be hydrolyzed by H2O.  This covalent binding reaction takes place very quickly with a 
half-life of 60 !sec. If the C3b is deposited on a non-activating surface, it will be quickly 
cleaved by Factor I (FI) with the help of a cofactor Factor H (FH) or membrane cofactor 
protein (MCP) and thereby be permanently inactivated.  However, if it is deposited on an 
activating surface, it will not be subject to immediate regulation and therefore 
complement activation will proceed and mark the target for phagocytosis or lysis.   
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Complement system regulation 
Due to the feedback loop of the AP, it is necessary to have regulators to prevent 
complement attack on healthy self-cells.  This regulation is provided by a combination of 
plasma and cell surface inhibitory proteins (Table 1).  Many of these proteins are encoded 
by a cluster of genes named the Regulators of Complement Activation (RCA) on 
chromosome 1
24
.  This gene locus includes membrane cofactor protein (MCP; CD46), 
Factor H (FH), Complement Receptor 1 (CR1; CD35), C4 binding protein (C4BP) and 
Decay Accelerating Factor (DAF; CD55).  A common structural feature of these RCA 
proteins is the complement control protein repeat (CCP).  These are about 60 amino acid 
units, usually encoded by a single exon, that are organized in a “beads on a string” 
arrangement.  
 MCP is a 60 kDa membrane protein expressed by most cells, except erythrocytes 
in man, and is composed of four contiguous CCP repeats.  FH is a serum protein of 150 
kDa composed solely of 20 contiguous CCPs.  CR1 is an ~250 kDa membrane protein 
whose ectodomain is composed of 30 CCP repeats.  C4BP is also a serum protein 
consisting of CCP domains.  It forms oligomeric structure, most often composed of seven 
" chains, each containing 8 repeats, and one # chain with three CCPs.  Finally, FI is a 100 
kDa plasma serine protease that is expressed on chromosome 4.  It is composed of a 55 
kDa heavy and a 35 kDa light chain that contains the catalytic domain.     
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There are two main mechanisms for regulation of the complement system:  decay 
accelerating activity and cofactor activity25 (Figure 1.3).  Decay acceleration protects 
cells from damage by inhibiting the assembly of the convertases on the cell surface, as 
well as disassembling those already present.  DAF, C4BP, CR1, and FH can all 
participate in DAA by enhancing the dissociation of C2a from C4b or Bb from C3b.  
Cofactor activity describes the permanent inactivation of C3b (or C4b) by proteolytic 
cleavage carried out by the serine protease FI.  For FI to bind C3b, C3b must first bind to 
a cofactor protein, which may be MCP, FH or CR1.  Then, FI can cleave C3b in two 
locations to release a small fragment, C3f, leaving iC3b on the membrane surface.  iC3b 
is unable to bind FB, thus blocking the amplification loop of the complement system.   
 
C3 
C3 is the central component of the complement cascade.  It is the most abundant 
complement protein in blood and is primarily synthesized by the liver
26
.  C3 has a MW of 
~190 kDa, being composed of 1663 amino acids that are encoded by 41 exons on 
chromosome 19 in humans.  It is a member of the "-2 macroglobulin family of proteins, 
which also includes two other complement components, C4 and C5, as well as the anti-
protease, "-2-macroglobulin.  C3 is translated as a single polypeptide chain (pro-C3), 
which is post-translationally cleaved to form the disulfide linked alpha and beta chains.  
Post-translational modifications of C3 include N-linked glycosylation at two sites and 
thioester bond formation (Figure 1.4).   
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Figure 1.3 :  Two mechanisms of complement regulation.  A.  Cofactor activity is 
carried out by FI in association with MCP, FH or CR1.  B.  Decay accelerating activity 
through FH in the fluid phase or DAF on the cell surface dissociates Bb from C3b (or 
C2a from C4b).   Adapted from Fang CJ. Br J Haematol 143:336-348, 2008  
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Figure 1.4: Diagram of the linear organization of C3 protein domains.  
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Thioester bond formation is a common feature of most members of the "-2 
macroglobulin family. It is a highly labile bond that, in C3, is formed between the 
cysteine residue in position 988 and the glutamine residue at 99127.  Upon activation of 
C3, the thioester bond is exposed and undergoes nucleophilic attack.  The free acyl-
imidazole group can now form an attachment to hydroxyl or amine groups on a target 
surface, with a preference for hydroxyls
28
.  The presence of an intact thioester can be 
assessed in several ways: susceptibility to autolytic cleavage, susceptibility to cleavage 
by a C3 convertase, and hemolytic activity
29
.  When proteins containing an intact 
thioester (C3, C4, "-2 macroglobulin) are subjected to heating under denaturing 
conditions, the thioester bond is susceptible to nucleophilic attack30.  The amino acid 
upstream of the cysteine attacks the bond and causes a break in the polypeptide chain.  
The result is two "-chain fragments observed on a reducing SDS-PAGE Western blot.  If 
the thioester has already been hydrolyzed, this cleavage cannot occur.   
Requirements for formation of an intact thioester have been suggested to include 
specific residues in the immediate area that can contribute bulky side chains that can pack 
around the thioester to exclude water
29,31
.  Specifically, two prolines (at positions 985 and 
998) have been shown to be absolutely critical to forming the thioester bond, these 
prolines are conserved in all species studied, including cobra and lamprey C3.  
Substituting these residues results in production of inactive C3 with no hemolytic or 
autolytic cleavage activity, or susceptibility to a C3 convertase.   
The mechanism of thioester bond formation has been investigated and debated, 
with no resolution to date.  One attractive hypothesis is that there may be a chaperone 
" !&
protein necessary for formation of this bond.  One study investigating thioester formation 
used a reticulocyte cell free protein synthesis system to generate C332.  This system is 
unable to generate an intact thioester bond.  However, when rabbit liver homogenates 
were added to this system, the C3 generated had an intact thioester.  Another study 
utilized C3 deficient guinea pigs
33
.  These animals were found to have normal C3 DNA 
and C3 specific mRNA.  Cells from these animals were able to synthesize C3, but that C3 
did not have an intact thioester and was more susceptible to trypsin digestion.  This data 
suggested that formation of the thioester is critical for secretion of stable C3, and that 
there is an extrinsic factor that is needed for thioester formation.  However, this factor, if 
it exists, has never been identified.  
The crystal structures of C3, C3b, and C3c have recently been solved,27,34,35 
providing interesting insights into C3 activation (Figure 1.5).  The structure and borders 
of the domains had not been previously predicted in part because they were found not to 
coincide with exon/intron borders (at all).  The beta chain is mostly composed of five 
macroglobulin domains (MG) of ~100 amino acids each that have very similar folds, 
despite having no sequence homology.  Interestingly, half of MG6 is encoded in the beta 
chain and half in the alpha chain.  The two halves of this domain are separated by the 
linker domain (LNK) of the beta chain as well as the C3a (anaphylatoxin; ANA domain) 
and "-NT! domains in the alpha chain, suggesting that these domains arose as insertions 
into the primitive C3 gene (Figure 1.4).  The "-chain also contains the thioester-
containing domain (TED) that is important for the attachment of C3 to targets.   
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Figure 1.5:  Crystal structure of complement C3.  Ribbon representation with each 
domain represented by a different color (corresponding to the colors in Figure 4).  The 
thioester residues are highlighted spheres (shown in red).   
Structure coordinates published in: Janssen, B.J. et al, Nature 437, 505-511 (22 
September 2005) 
" !(
 
Additionally, the "-chain possesses two more MG domains (MG7 and MG8), the CUB 
domain, and the C345C domain.  The CUB domain contains the cleavage sights for FI 
that are critical in the regulation of C3.  The function of the C345C domain has not been 
well defined.   Interestingly, all family members (C3, C4, and C5) contain this domain 
that appears to be sitting as the “head” of the protein.  In C3b, it appears important for 
interaction with Bb, while in C5, it has been shown that the C345C domain is important 
for binding to C6/7
36
.  
The proteolytic cleavage of C3 to C3b releases the ANA domain (C3a) and 
induces a substantial conformational rearrangement34,35 (Figure 1.6).  This change results 
in many new ligand binding epitopes being exposed.  C3b has multiple binding partners 
that include other complement components (C4b, FB, properdin, C2a, and C5), 
regulatory proteins (FH, MCP, FI, and DAF), and receptors (C3aR, CR1, CR2, CR3, 
CR4, and CRIg)
37,38
.  The binding sites on C3 for several of these binding partners have 
been described through mutagenesis, peptide blocking, and structural studies.  However, 
several interactions remain undefined.   
The activation product of C3 formed during the spontaneous tickover of the 
protein, C3(H2O), has long been thought to have a C3b-like structure.  This assumption 
was based on the fact that it can bind to the same ligands as C3b, as well as participate in 
the AP C3/C5 convertase.  The structure of C3(H2O) has been studied recently
39
.  The  
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 Figure 1.6: Schematic diagram of the conformational change during the C3 to C3b 
conversion. The "-chain is highlighted in blue, the #-chain in green and C3a is in cyan.  
The thioester residues are in red.   
 
 
 
 
 
 
" !*
data presented in this paper show that while C3(H2O) does undergo the dramatic 
conformational shift that is seen in C3b, the resulting structure is subtly different.  In 
C3(H2O), the TED and CUB domains are further extended from the body of the protein.  
However, the newly exposed sights are otherwise similar to those exposed in C3b, 
suggesting that the activity and ligand binding properties of these two activation products 
will be similar, which is in agreement with the previous literature.  In an EM study of C3 
and the activation products of C3 (C3b, C3(H2O) and iC3b), it was shown that there are 
multiple conformations that can be seen for each C3 state
40
.  This data suggests that there 
is quite a bit of flexibility in the conformational arrangement of these C3 activation 
products.   
 
C3 deficiency 
Complete C3 deficiency is a rare disorder.  In a 2000 review, 19 families were 
described worldwide with a genetic defect in C3
41,42
.  Of these families, those 
characterized are caused by point mutations or truncations.  Patients with a homozygous 
C3 deficiency present with pyogenic infections.  Specifically, infections with organisms 
such as Streptococcus pneumonia, Haemophilus influenzae, Staphylococcus aureus, and 
Neisseria meningitides are typically seen.  C3 deficiency may also lead to reduced 
efficacy of vaccination, with particularly poor antibody responses to encapsulated 
pathogens
11,12
.  Lack of C3 has also been associated with impairment in dendritic cell 
differentiation and maturation
13,43
.    
" #+
A secondary C3 deficiency may be induced when activation of complement is 
dysregulated.  Patients deficient in either of the regulatory proteins FI or FH consume 
their C341.  One function of Factors H and I is to control the spontaneous turnover of the 
AP in blood by inactivating C3b to iC3b by the protease FI.  If either of these regulatory 
proteins is missing, the AP cannot be held in check.  Another cause of secondary C3 
deficiency is C3 nephritic factor (C3-Neph).  It is an autoantibody to the AP C3-con that 
stabilizes the enzyme complex so that it does not decay normally.  In this manner, the 
convertase is over-activated and can turnover all of the C3.  Rarely, C4 nephritic factor 
(C4-Neph) has been described
44–46
.  It is an autoantibody that stabilizes the 
classical/lectin pathway C3 convertase (C4b2a) and also leads to consumption of C3.  
Secondary C3 deficiencies typically present with a glomerular renal disease termed 
membranoproliferative glomerulonephritis type II (MPGN II) or dense deposit disease 
(DDD).   
 
Atypical hemolytic uremic syndrome 
Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy 
that primarily affects the kidneys47. While the typical form of HUS (diarrheal positive) is 
primarily caused by infection with the Shiga toxin producing strains of E. coli48, the 
atypical form has been described as sporadic or familial, is non-enteropathic, and thought 
to be triggered by injury and other types of endothelial stress or damage
49,50
.  Patients 
with this disease generally present with the triad of microangiopathic hemolytic anemia 
(RBCs are sheared by fibrin strands), thrombocytopenia (platelets are consumed) and 
" #!
acute renal failure (due to clots in small blood vessels).  In aHUS, the underlying 
hypothesis for blood clot formation is complement activation that is excessive for the 
degree of endothelial injury.  
In the past decade, mutations in complement regulators have been shown to 
predispose to the development of aHUS.   Through genetic screening, mutations in the 
genes for MCP, FH, and FI have been identified in about 50% of aHUS patients
51
.  These 
mutations lead to insufficient regulation of the complement system.  The amplification 
loop of the AP is not held in check, resulting in an inappropriate acute inflammatory 
response that predisposes to microthrombi formation.  Autoantibodies to FH have also 
been identified in aHUS patients52.  Many of the patients with these autoantibodies were 
found to have a deletion of one or more of the FH-related genes53.   
Additionally, mutations in FB have been recently described
54,55
.  These mutations 
allow a higher affinity interaction between C3b and FB to occur.  They form a more 
stable C3 convertase and thus lead to the undesirable deposition of C3b on cells.  In 
contrast to the loss of function mutations in the regulatory proteins, these FB mutations 
are primary gain of function mutations.  In both situations, there is too much alternative 
pathway activation.  Finally, work to be presented here will describe mutations in the 
central component, C3, that have been recently identified in patients with aHUS.   
Treatment options for aHUS have been limited, with variable success
50
.  The use 
of plasma infusion or plasma exchange is temporarily helpful in some cases.  Kidney 
transplantion is usually unsuccessful due to recurrent aHUS.  It is now understood that 
the success or failure of the graft is largely dependent on the type of mutation the patient 
" ##
carries
53,56
.  If the patient carries a mutation in a plasma protein, the new kidney will still 
be susceptible to complement attack due to the dysregulation in blood.  However, if a 
patient has a mutation in the membrane protein MCP, the new kidney is more likely to 
survive because it now has the expected regulatory activity.  Recently, combined 
liver/kidney transplants in young infants with refractory aHUS have been reported that 
may have a greater chance of success
56
.   
Another treatment that has been used recently is Eculizumab (Alexion)
57–59
.  This 
drug is a function blocking monoclonal antibody against C5 that had been previously 
approved in use for treatment of paroxysmal nocturnal hemoglobinuria (PNH).  In several 
recent case reports, it was effective in aHUS patients and led to recovery of kidney 
function.  It is approved by the FDA to treat aHUS.  Additionally, in the recent outbreak 
of E. coli induced HUS in Europe, the drug may have been effective in some cases.    
The focus of this thesis work is on two human disease states, aHUS and 
secondary C3 deficiency, which can be attributed to defective complement regulation.  In 
the first set of studies, I will describe mutations in the central component, C3, and the 
studies that have been accomplished to elucidate the effect these mutations on the 
activation state of the complement system.  The second section of this thesis describes a 
patient with a secondary form of C3 deficiency and the efforts to discern the molecular 
mechanism of this deficiency.   
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CHAPTER 2 
Characterization of the functional consequences of C3 mutations in aHUS 
 
 
 
 
Some of the data presented in this chapter has been published in two papers: 
 
Frémeaux-Bacchi, V. et al. Mutations in complement C3 predispose to development of 
atypical hemolytic uremic syndrome. Blood 112, 4948-4952 (2008) © by the American 
Society of Hematology. 
 
Roumenina, L.T. et al. A prevalent C3 mutation in aHUS patients causes a direct C3 
convertase gain-of-function. Blood (2012). doi:10.1182/blood-2011-10-383281 © by the 
American Society of Hematology. 
 
These reports are reproduced in their entirety in Appendix 1 and 2. 
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INTRODUCTION 
 Hemolytic uremic syndrome (HUS) is a thrombomicroangiopathy that primarily 
affects the kidneys1.  It is characterized by microangiopathic hemolytic anemia (shearing 
of red blood cells), thrombocytopenia (consumption of platelets) and acute renal failure 
(caused by microthrombi in the renal vasculature). There are two forms, typical or 
enteropathic and atypical.  Typical HUS is the more common form and is associated with 
diarrheal (D+) E. coli infection in which the bacterium secretes a shiga toxin.  Atypical 
HUS (aHUS) is not preceded by a diarrheal illness and is familial or sporadic.  It is a rare 
disease, affecting 1 to 2 per 1,000,00002.  Compared to Shiga toxin based typical HUS, 
the rate of renal failure and severity of disease is much worse in aHUS, with 25% of 
patients dying and 50% of patients requiring dialysis
3
.   
Changes in complement levels have been observed in rare patients with HUS for 
many years
4
.  In the 1970’s it was noted that occassional patients with HUS had low 
serum C3 levels during the acute phase of the disease, which tended to normalize when 
the patient recovered.  Later in the same decade, low C3 levels as well as raised Factor B 
(FB) and C3 activation fragments were reported in a few patients with aHUS
4
.  Granular 
C3 deposits in the glomerulus and arterioles in aHUS patients have also been described5,6.  
Subsequently, two cases of siblings with a FH deficiency who developed aHUS were 
reported
7,8
.  Taken together, these data suggested a role for activation of the alternative 
pathway of complement in the pathogenesis of aHUS.     
 In 1998, a genetic association study employing satellite markers linked this 
disease to chromosome 1q32
9
, which encodes the genes for the regulators of complement 
" $#
activation
10
.  Following this observation, candidate gene sequencing was performed on 
complement genes.  Heterozygous mutations were identified in Factor H (FH) first11–13, 
followed by Factor I (FI)14–16 and membrane cofactor protein (MCP)17–20.  These 
regulatory genes control the level of C3 activation by permanently inactivating C3b such 
that it cannot participate in the amplification loop of the complement system’s alternative 
pathway (AP).  A relatively large number of mutations have now been identified in 
patients, and functional studies of the mutations have shown convincingly that, if the 
levels of regulatory proteins of the complement system are haploinsufficient, a 
predisposition to aHUS occurs.  
 Proper regulation of complement C3 is critical to maintain homeostasis; that is, to 
prevent inappropriate deposition on host tissues, but yet allow rapid deposition of C3 on a 
target.  C3 is the central component of the complement system and its activation is 
essential for complement function.  However, because of the efficient amplification loop 
of the alternative pathway, activation of C3 must be tightly controlled
21
.  Loss of 
regulation is detrimental to the host, leading to complement attacking self-tissues.  The 
importance of C3 as a susceptibility factor for human disease has been emphasized 
recently by studies documenting association of the polymorphism C3 R80G (C3 slow and 
fast) with both age-related macular degeneration22 and long-term renal allograft 
survival
23
.  This polymorphism had previously been tentatively associated with childhood 
cirrhosis, IgA nephropathy and partial lipodystrophy
24
.   
C3 is a complex protein. It undergoes multiple conformational changes following 
activation and then degradation by regulatory proteins
25
 (Table 2.1).  C3 in its native  
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Table 2.1.  Comparison of C3 and its activation products. 
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form is a substrate for the C3 convertases, bimolecular enzyme complexes that cleave C3 
to its active form, C3b26.  However, once activated to C3(H2O) by spontaneous tickover 
or C3b by convertases, a large number of protein-protein interactions become possible.  
This includes associations with other complement components as well as regulators and 
receptors.  C3b is degraded by limited proteolysis to iC3b and then C3c and C3dg 
through the action of the regulatory proteins.  These newly generated fragments also have 
distinct protein-protein interactions.  The binding sites for many of these proteins on C3b 
are just beginning to be defined
27–29
.  The naturally occurring mutations in C3 may give 
clues as to the location and quality of these protein-protein interactions.   
In this chapter I will describe the functional characterization of 16 C3 mutants.  
Our approach to study these proteins was to produce the proteins recombinantly and 
analyze their ability to interact with other complement proteins.  The initial hypothesis 
was that the mutations would lead to a loss of regulation, hence a secondary “over-
activation” state, leading to tissue destruction.  Another possibility was that the mutations 
would strengthen C3 binding to Factor B or properdin, thereby increasing convertase 
function.   
" $&
 
MATERIALS AND METHODS 
Materials 
 Purified C3, C3b, iC3b, Factor B (FB), Factor H (FH), Factor I (FI) and properdin 
were purchased from Complement Technologies (Tyler, TX).  Polyclonal antibodies to 
C3, Factor I and Factor H were also purchased from Complement Technologies.  The 
chicken anti-human C3 polyclonal antibody was from Biodesign International (Saco, 
ME).  A monoclonal anti-C3d antibody was from Quidel (San Diego, CA).  CM5 
BIAcore sensor chips were obtained from GE Healthcare.  Methylamine-hydrochloride 
was from Sigma (St. Louis, MO).   
 
Construct preparation 
 C3 cDNA was provided by David Isenman, Toronto in the pSV vector
30
 and was 
sequenced and compared to the published one.  Two single base pair changes were found 
in the cDNA and altered (QuikChange Multi Site-Directed Mutagenesis Kit; Stratagene, 
La Jolla, CA) to match the published sequence of the C3 used in the structural analysis
28
.  
Mutant C3 constructs were generated using the QuickChange XL Site-Directed 
Mutagenesis Kit from Stratagene.  Clones were sequenced to screen for the desired 
nucleotide substitution and then the selected clones were sequenced in their entirety to 
ensure that there were no other mutations.  Plasmid DNA was purified from E. coli 
cultures using the Promega Midi/Maxi Prep system.   
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Transient transfections   
Transient transfections were performed in mammalian cell lines in T-75 flasks.  
Chinese hamster ovary (CHO), Green monkey kidney epithelial (Cos-7) and Human 
embryonic kidney 293T (HEK 293T) cells were all transfected with 10 !g DNA per 
flask.  CHO cells were transfected with Fugene (Promega), COS cells with 
Lipofectamine (Invitrogen) and HEK 293T cells with TransIt-293 (Mirus).  Cells were 
incubated for 72 hrs in serum free DMEM, and supernatants were then collected and 
routinely concentrated approximately 40-fold.   
 
Western blotting   
C3 proteins produced by transient transfection were analyzed by Western blotting.  
Samples were electrophoresed on 10% Tris-glycine gels (Invitrogen).  Protein was 
transferred to nitrocellulose membrane at 25V for 90 min and membranes were blocked 
in 5% non-fat dry milk in PBS-T overnight.  Two antibodies, which recognize distinct 
epitopes, were used to assess C3.  The goat anti-human C3 polyclonal Ab was diluted 
1:5,000 and the chicken anti-human C3 polyclonal Ab was diluted 1:10,000 in 5% non-
fat dry milk.  The goat Ab recognizes both the "-chain and the #-chain, whereas the 
chicken Ab recognizes primarily the "-chain.  Membranes were incubated in the Ab for 1 
h at 37° C, followed by three 10 min washes in PBS-T.  Secondary Abs were a rabbit 
anti-goat IgG 1:3,000 or a donkey anti-chicken 1:10,000.  Membranes were incubated 
with the appropriate secondary Ab for 1 hr at RT, followed by washing in PBS-T.  Blots 
were developed using West Pico SuperSignal (Thermoscientific).   
" $(
Western blots for the regulatory proteins FI, FH, MCP and CR1 were also 
performed.  Samples were electrophoresed as above and probed with the following Abs at 
the indicated dilutions:  goat anti-human Factor I, (1:3,000), goat anti-human FH, 
(1:5,000), rabbit anti-human MCP, (1:5,000), and rabbit anti-CR1 (TP10), (1:10,000).   
 
C3 ELISA  
To determine the concentration of C3 in the transfection supernatants, a C3 
ELISA was performed
31
.  The anti-C3d monoclonal antibody was coated on ELISA wells 
at a concentration of 2 !g/ml in PBS (100 !l/well) and wells then incubated overnight at 
4° C.  Wells were next blocked with 10 mM Tris pH 7.4, 150 mM NaCl containing 1% 
BSA and incubated at 37° C for 90 min.  Standard curve and sample dilutions were 
prepared in 10 mM Tris pH 7.4, 150 mM NaCl containing 4% BSA.  Standard curves 
were prepared with purified serum C3 with a starting concentration of 10 ng/ml followed 
by serial 1:2 dilutions.  Dilutions of transfection supernatants were prepared in ELISA 
dilution buffer (minimum of 4).  Standard curve or sample (100 !l) was plated in each 
well and samples were incubated at 37° C for 90 min, followed by washing with Tris 
buffered saline with Tween (TBS-T).  The polyclonal chicken anti-human C3 (diluted 
1:10,000 in ELISA dilution buffer) was added (100 !l/well) and wells were incubated for 
1 hr at 37°C followed by washing with TBS-T.  The secondary antibody, donkey anti-
chicken IgG was next added (1:10,000 dilution) 100 !l/well.  Wells were incubated for 1 
hr at 37° C followed by washing with TBS-T.  Wells were developed using TMB 
Substrate (Pierce) and absorbance at 630 nm was determined.   
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Methylamine treatment of C3 proteins  
To inactivate C3, the proteins were treated with methylamine32.  A methylamine 
solution was prepared in 0.1 M Tris, pH 8.0 containing 0.4 M methylamine hydrochloride 
(Sigma, St. Louis).  The C3 proteins were mixed 1:1 with an equal volume of 
methylamine solution (final methylamine concentration of 0.2 M) and incubated at 37° C 
for 1 hr.   
 
Autolytic cleavage assay 
To assess the state of the thioester bond in the C3 preparations, the supernatants 
were subjected to the autolytic cleavage assay33.  C3 (20 ng) in 10 !l of PBS was mixed 
with 10 !l of 0.1 M Tris-acetate, pH 8.3 and 2 !L of 10% SDS.  After 1 h incubation at 
80°C, 11 µl of 3X reducing electrophoresis buffer was added. The sample was heated for 
5 min at 95°C and then electrophoresed on a 10% polyacrylamide gel. Western blot 
analysis using the polyclonal chicken anti-C3 antibody was employed to monitor the 
!"chain fragments.  
 
C3 purification: affinity column preparation  
For purification of recombinant C3 from the transfection supernatants, a CR1 
affinity column was prepared.  CR1 was coupled to CnBr-activated sepharose (GE 
Healthcare) following the manufacturer’s instructions.  Briefly, sepharose was activated 
by resuspending in 1 mM HCl, followed by washing four times with the HCl solution.  
After centrifugation, the sepharose was resuspended in 5 ml of 2 mg/ml solution of sCR1 
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in coupling buffer (NaHCO3, pH 8.3).  The sepharose and ligand were incubated 
overnight at 4° C, followed by washing in the coupling buffer.  Remaining active groups 
were blocked by addition of 0.1M Tris-HCl, pH 8.0.  Sepharose was washed with 
alternating cycles of 0.1 M acetic acid/sodium acetate pH 4.0 and 0.1 M Tris pH 8.0.  
Column was then washed with 5 mM KPO4, 25 mM NaCl buffer (pH 6.5) and stored at 
4° C.    
 
C3 purification  
C3(MA) preparations were applied to the CR1 column in KPO4 buffer, pH 6.5, at 
low salt (25 mM NaCl).  Following extensive washing, proteins were eluted using a 
stepwise salt gradient in 5 mM KPO4 buffer pH 6.5 (50-300 mM NaCl).  Intact C3(MA) 
eluted in the 150-250 mM NaCl fractions.  The fractions containing C3 were pooled 
together and assessed by silver staining for purity.  
 
ELISA based ligand binding assays   
 Proteins were coated on wells using 2 µg/ml of sMCP, FH, sCR1 (gift of H. Marsh, 
Avant Immunotherapeutics, Inc, Needham, MA) or FB in PBS overnight at 4°C.  This 
was followed by a blocking step at 37°C for 60 min (10 mM Tris, pH 7.4, with 25 mM 
NaCl, 1% BSA and 0.05% Tween-20). Dilutions of wild-type and mutant C3 proteins 
were prepared in a low salt ELISA buffer for the assessment of binding to sMCP, FH and 
sCR1 (10 mM Tris pH 7.4, 25 mM sodium chloride, 0.05% Tween 20, 4% BSA) or, for 
assessing binding to FB, in low salt buffer containing 10 mM MgCl2. Following an 
" %+
incubation at 37°C for 1 h, the sample was washed (10 mM Tris, 25 mM NaCl, 0.05% 
Tween) and affinity purified chicken anti-human C3 (1:10,000) was applied for 1 h at 
37°C. After washing, an HRP-linked donkey anti-chicken IgY (1:10,000) was applied for 
1 h at 37°C. Following washing, TMB substrate (Pierce) was added and absorbance was 
assessed at 630 nm. Values are given as % of binding to wild-type C3. These binding 
assays are typically carried out under low ionic strength conditions because of the low 
affinity of receptors and regulators to monomeric C3(MA) or C3b at physiologic ionic 
strength31.  
 
Cofactor assays  
 Cofactor assays were modified from a previously reported protocol
34
. C3 
preparations were incubated for 0 to 30 min at 37°C with factor I (5 ng in MCP assays 
and 20 ng in factor H assays) and a cofactor protein sMCP (50 ng, recombinant) or FH 
(200 ng) in 15 µl of buffer (10 mM Tris, pH 7.4, 150 mM NaCl). To stop the reaction, 7 
µl of 3X reducing Laemmli sample buffer was added. Samples were boiled at 95°C for 5 
min, electrophoresed on 10% Tris-glycine polyacrylamide gels, transferred to 
nitrocellulose and blocked overnight with 5% non-fat dry milk in PBS. These blots were 
probed with either a 1:10,000 dilution of chicken anti-human C3 (Biodesign 
International) followed by HRP-conjugated donkey anti-chicken IgG or, after stripping 
(see below), a 1:5000 dilution of goat anti-human C3 followed by HRP-conjugated 
donkey anti-goat IgG.  The blots were developed with SuperSignal substrate (Pierce).  
Membranes were stripped by washing with double-distilled water for 5 min, followed by 
" %!
washing in 0.2 M sodium hydroxide for 5 min and a final water wash of 5 min.  
 
Surface plasmon resonance   
SPR analysis was performed using the BIAcore 2000.  sMCP, FH, sCR1 and anti-
C3d mAb were coupled to individual flow paths using standard amine coupling 
technology from GE.  One flow path in each chip, lacking a coupled protein was 
activated as above to serve as a reference flow path.  The running buffer was composed 
of 10 mM Hepes, pH 7.4, 0.005% Tween-20 and NaCl (25 mM, 75 mM or 150 mM). 
Binding of serum C3, C3b and C3(MA) were assessed at multiple concentrations at the 
three different salt concentrations.  WT and mutant recombinant C3 proteins binding was 
assessed in low salt buffer only.  C3 proteins were injected for 90 sec at 30 !l/min.  
Following the injection, dissociation was monitored for 300 sec.  The chip was 
regenerated by injection of 0.5 M NaCl after each C3 injection.  Each protein was 
analyzed at four concentrations, with at least two injections performed per each 
concentration.   The experiments were performed with three independently produced and 
quantitated protein preparations.  Data was analyzed using the BIAeval software 
available from BIAcore.   
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RESULTS 
Identification of mutations 
 Sequencing of aHUS patients was performed by groups in France, England and 
the US.  The inclusion criteria for these studies were the presence of thrombocytopenia, 
microangiopathic hemolytic anemia, acute renal failure and normal functional activity of 
ADAMTS-13 (to rule out cases of TTP).  The initial sequencing for C3 mutations was 
performed on 26 patients, nine in England and 17 in France, who had consistently low C3 
serum levels and no mutations in FH, MCP, FI or FB.  Of this group, 11 patients had a 
C3 mutation.  Further analysis of patient’s families identified three affected individuals 
who had a C3 mutation and also suffered from aHUS.  Three of the mutations were in 
more than one patient, giving a total of nine distinct mutations (Table 2.2).  One 
mutation, R713W, was identified in both France and England.  Of these 14 patients, 
seven recovered renal function after the first episode of aHUS, and four of those went on 
to have recurrent episodes.  Among the 14 patients there have been twelve renal 
transplants, and five of these were affected by recurrent disease.  
 The family of one patient with the R570Q C3 mutation was analyzed separately in 
a follow up study35.  In this report, nine family members harbored this mutation.  All 
carriers showed reduced or borderline low C3 levels.  Chronic kidney disease was 
identified in two carriers, and five carriers had microhematuria.  Hypertension was 
present in six of these carriers, but in only one of the non-carrier family members.  This 
suggests that C3 mutations may be associated with not only aHUS but also may 
predispose to other disorders.     
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 After obtaining these results, the remainder of the French cohort was screened for 
mutations, regardless of their C3 serum levels.  Five additional mutations were identified 
(Table 1), K43N
#
, K133Q, R139W, I1073S and P1092L.  K43N was observed in two 
patients.  K133Q probably represents a rare polymorphism, being in four controls as well.  
I1073S and P1092L were in one patient each.  There was one C3 mutation, I734T 
identified in a patient with dense deposit disease (DDD), another complement related 
kidney disease.  
 R139W was seen in fourteen patients, representing about 50% of the patients with 
C3 mutations in the French cohort.  This mutation was not found in 550 normal controls.  
Most of the patients and 150 of the normal controls came from the north of France.  
Screening of healthy family members was also performed in some of the cases and 11 
healthy carriers were identified.  Patients carrying this mutation rapidly progressed to end 
stage renal failure (ESRF) and also showed an increased frequency of cardiac and 
neurologic complications.   
 An American group reported two additional C3 mutations in aHUS patients, 
F581V and R1020L
2
.  This group also identified a C3 mutation in a DDD patient, 
K1181R.   
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C3 protein production and purification 
Mammalian cell lines 
To produce the recombinant C3 proteins, transient transfections of mammalian 
cell lines three cell lines were initially tested:  CHO (Chinese hamster ovary), COS 
(Green monkey epithelial), and 293T (Human embryonic kidney) cells.  The use of COS 
cells for recombinant C3 production had been previously reported in the literature
36
, 
while CHO and 293T cells are routinely used in our laboratory for protein production.  
293T cells consistently produced the most C3.  However, the protein generated in these 
mammalian cell lines was not hemolytically active, as assessed by autolytic cleavage 
assays and hemolytic assays.   
To determine if the thioester bond was formed but then hydrolyzed, add-back 
experiments were performed.  In these experiments, purified serum C3 was added to the 
cell cultures, and the cultures were incubated for three days (to mimic our standard 
culture conditions).  The serum derived C3 ~50% of it’s hemolytic activity.  This result 
suggested that the secreted C3 is probably hemolytically inactive.  
 
Baculovirus protein production 
 To increase our protein yield as well as to generate hemolytically active protein, 
the baculovirus system of protein production was used to produce recombinant C3 in 
insect cells
37
.  The C3 cDNA was cloned into the pVL1393 baculovirus transfer plasmid 
and this vector was sent to Allele Technologies for virus production. Protein production 
" %'
was tested on a small scale in three cell lines:  Sf9, Sf21 and T.ni. C3 was produced in all 
cell lines, with Sf9 providing the highest yield.  However, upon scaling up in Sf9 cells, 
the C3 protein "-chain was degraded.  The virus was sent to Allele Technologies for 
protein production but they also obtained only degraded protein.  Due to the proteolytic 
cleavage of C3 in this system, this approach was not further pursued.  
 
Background cleavage in mammalian C3 production   
 Based on the above results, I decided to primarily produce the C3 proteins in 
293T cells.  Efforts were therefore made to increase the yield.  However, upon scaling up, 
a significant amount of background C3 cleavage was now present in the supernatants 
(Figure 2.1).  PMSF and a commercially available protease inhibitor cocktail (Roche) 
were added to the cultures but neither blocked the protein degradation.   
Two pieces of evidence led to the hypothesis that this cleavage was mediated by 
FI.  The first was that the degradation fragments observed by Western blotting of the cell 
supernatants had similar Mr to the fragments produced by FI cleavage of C3 "-chain.  
The second supporting piece of information was that the standard protease inhibitors 
could not block this cleavage.  It is known that the serine protease FI is not susceptible to 
blockade by most protease inhibitors38.   
 To assess if FI was present in the cell supernatants, Western blot analysis was 
performed.  FI was seen in all the supernatants (Figure 2.1B).  FI requires the presence of 
a cofactor protein (MCP, FH or CR1) to cleave C3.  Therefore, western blot analysis was 
also utilized to detect these cofactor proteins.  Bands corresponding to MCP but not FH  
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or CR1 were observed in the supernatants (Figure 2.1C).  Further, if blocking antibodies 
to either FI or MCP were added to the cultures at the time of transfection, this blocked the 
cleavage of C3 (Figure 2.1D).   
 
C3 purification 
Because there is a mixture of proteins in the transfections supernatants as well as 
C3 degradation products, purification of the C3 from the transfection supernatant was 
undertaken for SPR (surface plasmon resonance).  To accomplish this, an affinity column 
in which sCR1 is coupled to sepharose beads was prepared.  To test this column, purified 
C3b was mixed with conditioned media from 293T cells (to mimic transfection 
conditions).  After adjusting the ionic strength to 25 mM, the C3b was applied to the 
column.  The column was then washed extensively before the protein was eluted with a 
stepwise salt gradient of 25 to 300 mM NaCl in a phosphate buffer at pH 6.5.  Through 
this approach, I recovered C3b as expected and also separated it from the contaminating 
iC3b.  
To purify recombinant protein from the transfection supernatants, 293T 
supernatants were pooled, concentrated to a small volume, ionic strength was adjusted to 
25 mM NaCl, and then applied to the CR1 column.  Purified C3 was recovered with this 
method (Figure 2.2).  However, routinely a greater than 50% loss was observed.  
Therefore, most experiments discussed below were performed using transfection 
supernatants, and the purified protein was used in selected experiments.     
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C3 mutants in patients with low C3 
The initial sequencing for C3 mutations was performed in patients that presented 
with low C3.  There were nine mutations (in 14 patients) initially identified in these 
groups:  R570W, R570Q, R713W, Y832X, A1072V, D1093N, C1136W, Q1139K and 
H1442D.  R570W and R570Q are in the #-chain, while the others are in the "-chain.  The 
location of the mutants was mapped on the structure of C3 and C3b (Figure 2.3).   
 
C3 mutant expression 
Constructs of each of these mutants were prepared (with the exception of Y832X) 
and transient transfections of 293T cells performed.  The first observation was that 
C1136W was not secreted (Figure 2.4), being undetectable in the cell supernatants by 
Western blot or ELISA.  Upon preparing cell lysates, C1136W protein was observed, but 
at a reduced level compared to WT protein.  The intracellular C1136W protein also had a 
different Mr, suggesting that the protein was misfolded or degraded.  Other mutants were 
all expressed at levels similar to WT.               
 
C3 ligand binding assays 
Based on the data showing the critical involvement of regulatory proteins in the 
pathogenesis of aHUS, binding of the C3 mutants to the regulatory proteins MCP, FH 
and CR1 was assessed (Figure 2.5).  These assays revealed a deficiency in binding of C3 
to MCP by five mutants:  R570W, R570Q, A1072V, D1093N, and Q1139K.  These  
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mutants also had a corresponding defect in binding to Factor H, although the magnitude 
of the defect was less.  None of the mutants had a change in binding to CR1.   
FB binds to C3b to form the AP C3 pro-convertase, C3bB. FB is then converted 
by the serine protease Factor D to Bb, resulting in the functional AP-C3 convertase 
(C3bBb).  If C3b had enhanced binding to FB, this would lead to a gain of function 
convertase.  Therefore, the ability of the mutant C3 proteins to bind to Factor B was 
tested by ELISA.  None of the mutants had an altered level of Factor B binding, 
suggesting that the problem in these mutants is not a “super” AP C3 convertase.  
 
C3 Cofactor assays 
Fluid phase cofactor assays were performed to assess the time course of C3(MA) 
inactivation by the serine protease FI and the cofactor proteins MCP or FH (Figure 2.6).  
By monitoring the level of intact "-chain, as well as appearance of the "41-43 degradation 
products, modulation of C3 inactivation by FI can be assessed.  The MCP cofactor assays 
paralleled the results of the binding assays, with R570W, R570Q, A1072V, D1093N and 
Q1139K exhibiting reduced cofactor mediated cleavage.  In the FH cofactor assays, 
defective cleavage of the Q1139K protein was seen, while all other proteins exhibited 
normal levels of cleavage.   
These data represent the initial description of C3 mutations in aHUS.  The 
decrease in binding to the regulatory proteins leads to a secondary gain of function in 
these mutants.  Importantly, the location of these mutations is consistent with structural 
and mutagenic analysis of the binding site for FH on C3b.  In fact, in the year following 
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publication of this report, the structure of C3b-FH (1-4) was published
39
.  In that report, 
the C3 mutations described here served as a basis for verification of the structure.  
 
C3 mutants in patients with normal C3 levels 
Following the initial characterization of the first nine C3 mutations in aHUS, 
identified based on low C3 levels, all aHUS patients in several cohorts were screened for 
C3 mutations.  Five novel mutations were identified in the French cohort:  K43N, 
K133Q, R139W, I1073S, and P1092L.  Additionally, an American group recently 
reported that they screened for mutations in all complement genes known to be 
predisposing to aHUS in their patient cohort.  The novel C3 mutations they identified 
were F581V and R1020L.  Two C3 mutations were also identified in patients with a 
glomerulopathy known as dense deposit disease (DDD), I734T and K1181R.  In this 
section, I will describe my studies on eight of these mutations.  R139W is a special case 
and will be discussed in the next section.   
 The locations of the mutations are indicated on the crystal structure of C3b in 
Figure 2.7.  They localize to several domains on both chains.  K43N is in MG1, K133Q 
in MG2, F581V in LNK domain and I734T in the "!NT domain while R1020L, I1073S, 
P1092L and K1181R are in the TED domain.  As in my first study, many of the 
mutations are clustered in the TED domain.  Interestingly, there are also several 
mutations in domains not previously reported to house mutations (MG1, MG2, LNK and 
"!NT.   
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C3 ligand binding studies  
As in our previous study, we began by performing ELISA binding assays (Figure 
2.8).  The C3 mutants K43N, I1073S and R1020L had decreased binding (48, 34, and 
40% of WT binding, respectively) to MCP.  K133Q, F581V, P1092L and K1181R had 
unaffected MCP binding.  Interestingly, I734T had increased MCP binding, being 185% 
of WT.  Factor H binding assays indicated that K43N, K133Q, I734T, R1020L, I1073S 
and P1092L all had defective binding to this regulator, with levels of 65, 83, 71, 80, 48 
and 31% of WT.  The binding of F581V and K1181R to FH was only slightly reduced 
(not statistically significant).  All of the mutants had normal binding to CR1 and Factor 
B.  Thus, most of these new mutants exhibited defective binding to MCP, FH or both of 
the key C3b regulators.  
 
Cofactor assays 
Fluid phase cofactor assays were next performed employing MCP and FH as the 
cofactor protein to enable FI to cleave C3(MA).  Densitometric scanning of the "-chain 
was used to monitor cleavage of the "-chain chain over time.  I1073S exhibited a 
complete block in cleavage in MCP cofactor assays (summarized in Figure 2.9, Western 
blots are shown in Appendix 3, Figure A3.1 and A3.2).  R1020L had a 50% reduction in 
"-chain cleavage in the MCP cofactor assays.  The other mutants had normal levels of 
MCP mediated cleavage.  In FH cofactor assays, K133Q, R1020L, I1073S and P1092L 
had substantially reduced " chain cleavage.   
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Surface plasmon resonance (SPR) analysis  
To further define the interactions of the mutant C3 proteins with complement 
regulatory proteins, SPR experiments were performed.  The initial strategy was to couple 
purified WT and mutant C3 proteins to a CM5 Biacore sensor chip, and then flow over 
the ligands (MCP, FH, CR1).  However, all attempts to couple the C3 to the chip failed.  
The most likely explanation for this is that the C3 concentrations were too low to 
effectively couple to the chip.  In fact, if purified serum C3(MA) was diluted to 
concentrations that were similar to those of the recombinant protein, coupling to the chip 
was also impaired; however, C3(MA) was able to couple to the chip when it was applied 
at higher concentrations.  
Next, I tried antibody capture.  Antibody to C3 was coupled to the chip and then 
the C3 proteins were applied.  The ligand of interest could then be applied to the flow 
paths.  Four different monoclonal antibodies were tested, and only one of them was able 
to form a complex with C3(MA).  However, this complex dissociated quickly and also 
raised the concern that a mAb might mask important epitopes.  This method was not 
further pursued.  
 Coupling of the ligands to the chip by amine coupling was then examined.  With 
the ligands coupled to the chip, the C3(MA) proteins became the analyte.  Initially, serum 
derived purified C3(MA) protein was used to define the parameters of the system.  The 
binding of C3(MA) and C3b (positive controls) was tested at multiple concentrations and 
at two ionic strengths (Figures 2.10-2.11).  Dose response curves were generated in 150 
mM NaCl containing buffer and analyzed using the 1:1 Langmuir binding model in the  
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BIAeval software to determine kinetic parameters.  At 25 mM NaCl, a dose response was 
again seen, but in this case it did not fit well to the models.  This is not entirely surprising 
as these curves were generated in a low salt buffer, whereas the models assume a 
physiologic ionic strength.  Nevertheless, in both cases reproducible, dose-dependant 
binding curves of the C3 proteins interacting with MCP and FH were generated. 
 To further analyze the system, Scatchard and nonlinear regression analyses were 
performed (Figures 2.10-2.11). This analysis demonstrated that equilibrium was not 
reached, making a strict quantitative analysis problematic.  Qualitative differences can 
still be appreciated.   
 Having established the parameters of this system, the C3 mutant proteins were 
analyzed.  It quickly became apparent that these assessments would need to be done in 
low salt buffer (25 mM NaCl).  The low concentration of the recombinant proteins 
prohibited their use at 150 mM NaCl.  The C3 mutants, treated with methylamine to 
assure conformational homogeneity, were flowed over the chip at various concentrations 
(0.1 nM to 5 nM) for 90 sec, followed by a dissociation period of 300 sec.  Between each 
injection, 0.5 M NaCl was injected for 10 sec as a regeneration step followed by washing 
of the flow cells.   
 In a comparison of WT to the mutant C3 proteins, six mutants (K43N, K133Q, 
F581V, R1020L, P1092L, and K1181R) demonstrated reduced binding to MCP (Figure 
2.12).  In one mutant, I1073S, the binding levels were similar to those of WT.  In the FH 
binding sensorgrams, all mutants demonstrated reduced binding to FH (Figure 2.13).  To 
confirm that the recombinant proteins injected were at the same concentration, the fourth  
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flow path was coupled with an anti-C3d monoclonal antibody and levels of C3 binding 
were monitored.  The overlays show that the proteins were injected at equivalent levels 
(Figure 2.12 and 2.13C).  Titration overlays for all of the mutants tested are shown in 
Appendix 3 (Figures A3.3 and A3.4).  
 The results of these experiments confirm that these mutations lead to a resistance 
to inhibition by regulatory proteins.  Reduced binding capacity to one or both regulators 
was observed for all mutants.  Additionally, this result translates to a reduction in FI 
mediated cofactor cleavage of the protein.    
The comparison of ELISA and the SPR data demonstrate that more than one 
method should be used to assess mutation defects.  In the ELISA, some changes in 
regulator binding by the mutants did not appear to be significant; however, when 
analyzed by SPR, a defect was apparent.  This may simply be that the SPR experiments 
are more sensitive.  It may also be due to a difference in the orientation of the proteins. 
 
Studies on the C3 mutant R139W 
R139W is a prevalent mutation that has been identified in 14 patients in the north 
of France.  It was not identified in 150 normal controls taken from the same region.   
 
R139W binding to regulators 
Binding to the proteins MCP, FH, CR1 and Factor B was assessed for this mutant.  
Binding of R139W C3 to MCP was reduced to about 35% of WT binding in the ELISA  
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binding assays (Figure 2.14).  The binding of R139W to FH, however, was similar to WT 
levels.  Interestingly, binding of R139W to CR1 was modestly reduced (70% of WT 
binding).  R139W is the only C3 mutant seen to have a reduction in binding to CR1.  To 
confirm the ELISA binding data, SPR analysis was next performed with MCP or FH 
coupled to the chip (Figure 16).  In these experiments, R139W was again seen to have a 
decrease in binding to MCP, but not FH. 
 
C3 cofactor assays  
 Fluid phase cofactor assays employing MCP, FH or CR1 as the cofactor protein 
demonstrated a delay in MCP mediated cleavage of R139W as compared to WT as well 
as an alteration in the cleavage fragments generated (Figure 2.15).  With the WT protein, 
there was transient generation of the "43 fragment that precedes the "41 fragment 
generation.  With the R139W protein, there was a change in this pattern.  The "43 was 
more prominent than "41 at all time points, suggesting that the mutation is affecting the 
second FI cleavage site resulting in more of the larger sized fragment.   
 In cofactor assays utilizing FH and CR1, there was no delay in cleavage in the " 
chain, suggesting that there was no significant alteration in binding to FH and CR1 by 
R139W, and supporting the data from the binding assays.  However, a distinct cleavage 
pattern was again seen.  The "43 fragment was a darker band than "41 in both assays.  This 
result further suggests that R139W mutation has an effect on the ability of FI to cleave at 
the second location  (perhaps due to a steric effect).   
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Factor B binding by R139W 
 To analyze the interaction of R139W with Factor B, ELISA binding studies were 
performed.  In these assays, R139W had a higher level of binding to FB than WT C3.  To 
determine whether this increase in binding translated to a hyperfunctional convertase, the 
AP C3 convertase was assembled on the BIAcore chip.  C3 (WT or R139W) was injected 
along with Factor B and Factor D.  Following convertase assembly, C3 by itself was 
injected.  The convertase formed with R139W was more efficient, leading to more C3b 
being deposited on the chip.   
 The R139W mutation is the first description of a C3 mutation with a double-hit.  
This mutation has lost susceptibility to regulatory proteins but also experienced a gain of 
function relative to its FB interactions.   
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DISCUSSION 
 The characterization of 16 mutations in human C3 identified in aHUS patients and 
two mutations in patients with DDD is described here.  The majority had a decrease in 
their susceptibility to regulation by FH and/or MCP (summarized in Table 3.3).   
Additionally, two mutants (one in this study and one report from another group
40
) have 
an increased binding activity with Factor B, leading to a more stable C3 convertase.  In 
either situation, though, the end result is the same- increased complement activation.  In 
aHUS, this presumably leads to endothelial cells in the microvasculature of the kidney 
becoming having a more procoagulant phenotype.   
 The studies presented here represent the first description of C3 mutations 
associated with aHUS.  Prior studies provided evidence that mutations in the negative 
regulators of complement predispose to aHUS
12–15,17,41,42
.  The work presented here, 
together with the recent studies of FB
43,44
, provides clear evidence that a primary gain of 
function in activating proteins of the AP also predispose to aHUS.  Altogether, ~70% of 
aHUS cases can be explained by a mutation in one of the regulatory proteins, C3 or FB, 
or by the presence of autoantibodies to FH45,46.  Additionally, common haplotype risk 
factors are now being identified that may be a second hit along with a heterozygous 
mutation to lead to disease
3,47
.   
The majority of the aHUS patients are heterozygous and the patients have about 
half normal levels of the WT protein.  There are three major negative regulators involved 
in control of the C3 activation.  A single point mutation in any one of these regulatory 
" ($
proteins predisposes to aHUS.  Haploinsufficiency is thus not adequate to maintain 
homeostasis.  These proteins do not have overlapping functions. They are not redundant, 
as was proposed initially by multiple groups.  A 50% decrease in any one predisposes to 
aHUS.   
 In these studies, there were two cases of C3 haploinsufficiency, Y832X and 
C1136W.  They do not fit the paradigm of a gain of function in an activating protein 
predisposing to aHUS.  A case of haploinsufficiency of an activating protein should 
protect an individual from aHUS secondary to a lesser amount of C3 available for the AP.  
These mutations may be merely coincidental to the disease pathogenesis and 
development of aHUS. 
 The mutations described here also lend insight into the domains of C3 important 
for interactions with regulatory proteins.  There have been reports (prior to the crystal 
structure of C3) of peptide sequences important for FH, CR1, and MCP interactions with 
C3.  The structure of C3b in complex with FH 1-4 has been recently solved
39
. In this 
structural report, the authors determined that repeats 1-4 of FH contact C3b in multiple 
locations including in the "!NT, MG1, MG2, MG6, MG7, CUB and TED domains.  
Additionally, they mapped the mutations described in our first group of patients and 
found that most of these mutants with a defect in binding to FH mapped to the binding 
interface.  These findings are therefore a conformation of our functional studies.   
 Recent reports of the interactions of C3b with FH domains 19-20 indicate that 
FH19-20 interacts with an area of the TED domain that is separated from the FH 1-4 
interface.  FH 1-4 is responsible for the cofactor activity, while FH 19-20 binds to C3b 
" (%
and to anionic surfaces.  Interestingly, one of the C3 mutants studied here (P1092L) is in 
the FH 19-20 binding region and had decreased FH binding.  However, in my cofactor 
assays there was reduced cleavage of P1092L C3 by FH, suggesting that this binding 
interface may also influence FH 1-4 mediated cofactor activity.   
 The relative severity of aHUS associated with C3 mutations has yet to be well 
defined due to the small number of cases reported.  Mutations in FH and FI lead to the 
worst outcome.  However, aHUS in patients with C3 and FB mutations may also be as 
severe.  Patients carrying MCP mutations have the best prognosis, probably because a 
donor kidney will replace the mutated MCP with normal MCP.  With the recent 
identification of additional C3 mutations48, we will be able to compile more data on the 
disease progression of C3 associated aHUS.   
" (&
2&3%"+:5:5""1$.0'-(.&%+0(.7"U$".0"+(8+9:+<$'&'-(.7+-.+&FGH+6&'-".'75" 
"
JG2SV2+
R/IHS+WIVXIVY+ 9Z1S92Z!+SHHS[+ WIS9Z!R+
1F+ J9,+ 1F+ J9,+ 1F++ J9,+
\C:V+ ]]+ ]+ ]]]+ ]]^]]]+ !+ !+
\4::_+ ]]+ ]]]+ ]+ ]]]+ !+ !+
!4:>N+ ]]]+ ]+ ]]]+ ]]+ V+ !+
!OQD_+ ]]+ ]+ ]]]+ ]+ V2+ V2+
!OQDN+ ]]+ ]+ ]]]+ ]+ V2+ V2+
1OB4`+ ]]]+ ]]]+ ]]]+ ]]]+ !+ !+
!Q4:N+ ]]]+ ]]]]+ ]]]+ ]]]+ V2+ V2+
IQ:C2+ ]]+ ]]]]+ ]]]+ ]]]+ V2+ V2+
!4D=D/+ ]]+ ]+ ]+ ]+ !+ !+
S4DQ=`+ ]]+ a+ ]]]+ a+ V2+ V2+
I4DQ:H+ ]+ ]+ ]+ a+ !+ V+
,4D>=/+ ]+ ]]]]+ ]]]+ ]]^]]]+ !+ !+
X4D>:V+ ]]+ a+ ]]]+ ]+ V2+ V2+
_44:>\+ ]]+ ]]+ ]+ a+ V2+ V2+
\44B4!+ ]]+ ]]]+ ]]]+ ]]]+ !+ !+
F4CC=X+ ]]]+ ]]]]+ ]]]+ ]]]+ V2+ V2+
"
" ('
3GD5GDO"-88-N"-./GRG/N"[-8"O1-5@5"-8"E0440[8Q""uuuu<"d!!+oH"uuu<"*+Z!!+oH"uu<"&+Z
)*oH"u<"#+Z%*oH""v<"c"#+oT"""
=0E-./01"-./GRG/N"[-8"5@EGD@5"-8Q""uuu<"D019-4H"uu<"&+Z*+o"0E"WPH"u<"#+Z&+o"0E"WPH"
v<"c"#+o"0E"WPT"""
,01"3G-.01@"-D-4N8G8"!w" 4@88" /I-D"WP"CGD5GDO" 4@R@48<"Mw"D019-4" 4@R@48"0E"CGD5GDO<"
"wGD.1@-8@5"CGD5GDO".097-1@5"/0"WP"=$T""
 
" ((
References:  
1. Kavanagh, D., Richards, A. & Atkinson, J. Complement Regulatory Genes and 
Hemolytic Uremic Syndromes. Annual Review of Medicine 59, 293-309 (2008). 
2. Maga, T.K., Nishimura, C.J., Weaver, A.E., Frees, K.L. & Smith, R.J.H. Mutations in 
alternative pathway complement proteins in American patients with atypical 
hemolytic uremic syndrome. Hum. Mutat. 31, E1445-1460 (2010). 
3. Kavanagh, D. & Goodship, T.H.J. Atypical hemolytic uremic syndrome, genetic 
basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011, 
15-20 (2011). 
4. Noris, M. & Remuzzi, G. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 
361, 1676-1687 (2009). 
5. Barré, P., Kaplan, B.S., de Chadarévian, J.P. & Drummond, K.N. Hemolytic uremic 
syndrome with hypocomplementemia, serum C3NeF, and glomerular deposits of C3. 
Arch. Pathol. Lab. Med. 101, 357-361 (1977). 
6. Hammar, S.P., Bloomer, H.A. & McCloskey, D. Adult hemolytic uremic syndrome 
with renal arteriolar deposition of IgM andC3. Am. J. Clin. Pathol. 70, 434-439 
(1978). 
7. Pichette, V. et al. Familial hemolytic-uremic syndrome and homozygous factor H 
deficiency. Am. J. Kidney Dis. 24, 936-941 (1994). 
8. Thompson, R.A. & Winterborn, M.H. Hypocomplementaemia due to a genetic 
deficiency of beta 1H globulin. Clin. Exp. Immunol. 46, 110-119 (1981). 
" ()
9. Warwicker, P. et al. Genetic studies into inherited and sporadic hemolytic uremic 
syndrome. Kidney Int. 53, 836-844 (1998). 
10. Hourcade, D., Holers, V.M. & Atkinson, J.P. The regulators of complement 
activation (RCA) gene cluster. Adv. Immunol. 45, 381-416 (1989). 
11. Dragon-Durey, M.-A. et al. Heterozygous and homozygous factor h deficiencies 
associated with hemolytic uremic syndrome or membranoproliferative 
glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15, 
787-795 (2004). 
12. Richards, A. et al. Factor H mutations in hemolytic uremic syndrome cluster in exons 
18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68, 485-490 
(2001). 
13. Manuelian, T. et al. Mutations in factor H reduce binding affinity to C3b and heparin 
and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. 
Invest. 111, 1181-1190 (2003). 
14. Kavanagh, D. et al. Mutations in complement factor I predispose to development of 
atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 2150-2155 (2005). 
15. Fremeaux-Bacchi, V. et al. Complement factor I: a susceptibility gene for atypical 
haemolytic uraemic syndrome. J. Med. Genet. 41, e84 (2004). 
16. Kavanagh, D. et al. Characterization of mutations in complement factor I (CFI) 
associated with hemolytic uremic syndrome. Mol. Immunol. 45, 95-105 (2008). 
17. Noris, M. et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 
362, 1542-1547 (2003). 
" (*
18. Richards, A. et al. Implications of the initial mutations in membrane cofactor protein 
(MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol. Immunol. 44, 
111-122 (2007). 
19. Fang, C.J. et al. Membrane cofactor protein mutations in atypical hemolytic uremic 
syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. 
Blood 111, 624-632 (2008). 
20. Richards, A. et al. Mutations in human complement regulator, membrane cofactor 
protein (CD46), predispose to development of familial hemolytic uremic syndrome. 
Proc. Natl. Acad. Sci. U.S.A. 100, 12966-12971 (2003). 
21. Holers, V.M. The spectrum of complement alternative pathway-mediated diseases. 
Immunol. Rev. 223, 300-316 (2008). 
22. Spencer, K.L. et al. C3 R102G polymorphism increases risk of age-related macular 
degeneration. Human Molecular Genetics 17, 1821-1824 (2008). 
23. Varagunam, M., Yaqoob, M.M., Döhler, B. & Opelz, G. C3 polymorphisms and 
allograft outcome in renal transplantation. N. Engl. J. Med. 360, 874-880 (2009). 
24. Heurich, M. et al. Common polymorphisms in C3, factor B, and factor H collaborate 
to determine systemic complement activity and disease risk. Proceedings of the 
National Academy of Sciences 108, 8761-8766 (2011). 
25. Janssen, B.J.C. & Gros, P. Structural insights into the central complement component 
C3. Mol. Immunol. 44, 3-10 (2007). 
26. Lambris, J.D. The multifunctional role of C3, the third component of complement. 
Immunol. Today 9, 387-393 (1988). 
" )+
27. Wu, J. et al. Structure of complement fragment C3b-factor H and implications for 
host protection by complement regulators. Nat. Immunol. 10, 728-733 (2009). 
28. Janssen, B.J.C. et al. Structures of complement component C3 provide insights into 
the function and evolution of immunity. Nature 437, 505-511 (2005). 
29. Janssen, B.J.C., Christodoulidou, A., McCarthy, A., Lambris, J.D. & Gros, P. 
Structure of C3b reveals conformational changes that underlie complement activity. 
Nature 444, 213-216 (2006). 
30. Taniguchi-Sidle, A. & Isenman, D.E. Mutagenesis of the Arg-Gly-Asp triplet in 
human complement component C3 does not abolish binding of iC3b to the leukocyte 
integrin complement receptor type III (CR3, CD11b/CD18). J. Biol. Chem. 267, 635-
643 (1992). 
31. Liszewski, M.K. et al. Dissecting sites important for complement regulatory activity 
in membrane cofactor protein (MCP; CD46). J. Biol. Chem. 275, 37692-37701 
(2000). 
32. Micklem, K.J., Sim, R.B. & Sim, E. Analysis of C3-receptor activity on human B-
lymphocytes and isolation of the complement receptor type 2 (CR2). Biochem. J. 
224, 75-86 (1984). 
33. Sim, R.B. & Sim, E. Autolytic fragmentation of complement components C3 and C4 
and its relationship to covalent binding activity. Ann. N. Y. Acad. Sci. 421, 259-276 
(1983). 
" )!
34. Liszewski, M.K., Leung, M.K. & Atkinson, J.P. Membrane cofactor protein: 
importance of N- and O-glycosylation for complement regulatory function. J. 
Immunol. 161, 3711-3718 (1998). 
35. Lhotta, K. et al. A Large Family with a Gain-of-Function Mutation of Complement 
C3 Predisposing to Atypical Hemolytic Uremic Syndrome, Microhematuria, 
Hypertension and Chronic Renal Failure. Clinical Journal of the American Society of 
Nephrology 4, 1356-1362 (2009). 
36. Clemenza, L. & Isenman, D.E. Structure-guided identification of C3d residues 
essential for its binding to complement receptor 2 (CD21). J. Immunol. 165, 3839-
3848 (2000). 
37. Lambris, J.D. et al. Dissection of CR1, factor H, membrane cofactor protein, and 
factor B binding and functional sites in the third complement component. J. Immunol. 
156, 4821-4832 (1996). 
38. Nilsson, S.C., Sim, R.B., Lea, S.M., Fremeaux-Bacchi, V. & Blom, A.M. 
Complement factor I in health and disease. Molecular Immunology 48, 1611-1620 
(2011). 
39. Wu, J. et al. Structure of complement fragment C3b-factor H and implications for 
host protection by complement regulators. Nat. Immunol. 10, 728-733 (2009). 
40. Sartz, L. et al. A novel c3 mutation causing increased formation of the c3 convertase 
in familial atypical hemolytic uremic syndrome. J. Immunol. 188, 2030-2037 (2012). 
" )#
41. Liszewski, M.K., Leung, M.K., Schraml, B., Goodship, T.H.J. & Atkinson, J.P. 
Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome. 
Mol. Immunol. 44, 1559-1568 (2007). 
42. Goodship, T.H.J., Liszewski, M.K., Kemp, E.J., Richards, A. & Atkinson, J.P. 
Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. 
Trends Mol Med 10, 226-231 (2004). 
43. Roumenina, L.T. et al. Hyperfunctional C3 convertase leads to complement 
deposition on endothelial cells and contributes to atypical hemolytic uremic 
syndrome. Blood 114, 2837-2845 (2009). 
44. Goicoechea de Jorge, E. et al. Gain-of-function mutations in complement factor B are 
associated with atypical hemolytic uremic syndrome. Proc. Natl. Acad. Sci. U.S.A. 
104, 240-245 (2007). 
45. Dragon-Durey, M.-A. et al. Anti-Factor H autoantibodies associated with atypical 
hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16, 555-563 (2005). 
46. Moore, I. et al. Association of factor H autoantibodies with deletions of CFHR1, 
CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with 
atypical hemolytic uremic syndrome. Blood 115, 379-387 (2010). 
47. Kavanagh, D. & Goodship, T.H.J. Atypical hemolytic uremic syndrome. Curr. Opin. 
Hematol. 17, 432-438 (2010). 
48. Noris, M. et al. Relative Role of Genetic Complement Abnormalities in Sporadic and 
Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the 
American Society of Nephrology 5, 1844-1859 (2010). 
" )$
 
 
 
 
 
 
 
 
CHAPTER 3 
Autoimmunity to the classical pathway C3 convertase leading to C3 
deficiency and Neisseria meningitidis septicemia and meningitis 
" )%
Introduction 
Primary C3 deficiency is a rare disorder, in a 2000 review it was described in 19 
families worldwide1.  Patients with a C3 deficiency typically present with recurrent 
pyogenic infections cause by primarily encapsulated organisms such as E+-("@)&.&..9/$
-97#9/N" D-#'&("5)9/$ 5*K)9#*O-#<" E+7#(+&.&..9/$ (*#9'&*5-#N" -D5" =#5//#75-$
'#*5*65+54#/:$  These infections can lead to sepsis and become life-threatening
1,2
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5@EG.G@D.N" 9-N" -480" 1@5J.@5" /I@" @EEG.-.N" 0E" R-..GD-/G0D<" [G/I" 7-1/G.J4-14N" 7001"
-D/GC05N"1@870D8@8"/0"@D.-78J4-/@5"7-/I0O@D8$<%T""The genetic cause of a primary C3 
deficiency is commonly either an amino acid substitution that may lead to protein 
misfolding, or a premature stop codon
1,5,6
.   
Secondary C3 deficiency is seen in patients that synthesize C3 protein normally, 
but its consumption is accelerated. These patients may have a deficiency in a C3 
regulatory protein such as Factor H (FH) or Factor I (FI)1.  Deficiency in either of these 
inhibitors causes accelerated alternative pathway (AP) turnover and excessive turnover of 
C3. Another cause of secondary C3 deficiency is an autoantibody to the AP C3 
convertase, C3bBb
7
.  These antibodies are known as C3 nephritic factors (C3-Neph) due 
to their association with glomerular renal disease.  When patients carry a C3-Neph, the 
C3 convertase is stabilized indefinitely and thus converts (by proteolysis) C3 to C3b.  
This C3b is then fragmented by FI in conjunction with a cofactor protein and the 
resulting proteolytic pieces are cleared from the circulation.  More rarely, C4-nephritic 
factor (C4-Neph) has been reported8–10.  C4-Neph is an autoantibody that stabilizes the 
" )&
classical pathway convertase, C4b2a, and has been reported in a few patients with 
glomerular disease and two patients with lupus.   
The C3 convertases are bimolecular enzyme complexes that cleave C3 to C3a and 
C3b
11
.  The C3 convertase shared by the classical and lectin pathways (CP/LP) is 
composed of two subunits, C4b, which attaches covalently to the target, and the catalytic 
subunit C2a.  The AP C3 convertase consists of C3b and the serine protease Bb, the large 
catalytic subunit of the zymogen Factor B.  The convertase subunits are attached to one 
another non-covalently.  The complexes are relatively unstable, each having a half-life of 
less than five min.  Regulators in the blood and on cell surfaces can accelerate decay.  
These proteins include FH, Decay Accelerating Factor (DAF), Complement Receptor 1 
(CR1) and C4 binding protein (C4BP)12.  C4BP specifically accelerates decay of the 
CP/LP convertase, FH is specific for the AP convertase, and CR1 and DAF are able to 
regulate the both the CP/LP and AP convertases. 
>D"/IG8".I-7/@1<"[@"8/J5G@5"-D"!)ZN@-1Z045"7-/G@D/"[G/I"-"EG18/Z/G9@"=#5//#75-$
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Materials and Methods 
Materials   
Purified human complement proteins (C1, C2, C3, C3b, iC3b, C3c, C3d, C4, FB, 
C4 binding protein, and properdin), polyclonal antibodies against C3, FB and properdin 
and antibody sensitized sheep erythrocytes (EA cells) were purchased from Complement 
Technologies (Tyler, TX). A polyclonal antibody against C4 binding protein was 
purchased from AbCam (Cambridge, MA).  Protein G agarose was obtained from 
Thermo Scientific (Rockford, IL).  DGVB
++ 
buffer (veronal buffered saline: 0.015% 
sodium 5!, 5!!-diethylbarbiturate (pH 7.35) and 71 mM NaCl supplemented with 2.5% 
dextrose, 0.1% gelatin, 1 mM MgCl2 and 0.15 mM CaCl2) was prepared as described 
previously
13
. EDTA-GVB buffer contained 0.1% gelatin, 0.015% sodium 5!, 5!!-
diethylbarbiturate (pH 7.35), 71 mM NaCl and 40 mM EDTA13.  
 
Sample collection   
Informed consent was obtained under a protocol at Children’s Hospital of 
Wisconsin approved by their internal review board.  Blood samples were procured from 
the patient in EDTA vacutainer tubes for DNA analysis.  For serum samples, blood was 
allowed to clot for 30 min at RT and, after centrifugation, the serum was removed and 
frozen in aliquots until analysis.   
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Genomic sequencing  
DNA was isolated from the peripheral blood of the patient using a QIAmp Blood 
Maxi Kit (Qiagen, Valencia, CA).  Sequencing primers for genomic C3 were designed 
using the Primer 3 software.  Twenty-eight pairs of primers were used to cover the 41 
exons and intron/exon borders.  A minimum of 50 base pairs into each intron was 
sequenced.  Primer sequences are listed in Table 1.  
 
Western blotting   
For C3 analysis, sera and purified complement proteins were electrophoresed on 
10% Tris-Glycine polyacrylamide gels followed by transfer to a nitrocellulose 
membrane14.  Membranes were blocked overnight with 5% non-fat dry milk in Phosphate 
Buffered Saline-Tween (PBS-T).  Blots were probed with a 1:5,000 dilution of a goat 
anti-human C3 antibody (Complement Technologies, Tyler, Texas), followed by a rabbit 
anti-goat IgG HRP secondary antibody (Sigma, St Louis, MO).  The blots were 
developed with Super Signal West Pico Substrate (Thermo Scientific, Rockford, IL).   
 
C3 ELISA   
Native C3, C3b and iC3b were coated on ELISA wells at 2 !g/ml in PBS. After 
overnight incubation at 4°C, wells were blocked with TBS (10 mM Tris, pH 7.4, 150 mM 
NaCl) containing 1% BSA.  Serum samples were diluted in TBS containing 4% BSA and 
applied to the ELISA wells.  Following an incubation at 37 °C, samples were removed by 
washing with TBS-Tween.  Secondary antibodies to IgG or IgM were applied to the wells  
" ))
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(goat anti-human IgM (Sigma) or donkey anti-human IgG (Jackson Immunoresearch) 
using a 1:3000 dilution and plates were incubated for 1 h at 37 °C. Following a washing 
step, plates were developed using TMB substrate (Thermo Scientific) and the absorbance 
at 630 nm was determined
15
.  
 
Preparation of EAC14b2a cellular intermediates   
The classical pathway C3 convertase was assembled on antibody-sensitized sheep 
erythrocytes (EA) as previously described
16,17
.  Briefly, EA cells (5 ! 10
8 
cells/ml) were 
washed three times in DGVB
++
.  Purified human C1 was added to the cells and incubated 
at 30° C for 15 min, followed by washing in DGVB++.  Next, human C4 was added and 
cells were incubated for 15 min at 30° C, followed by washing in DGVB++.  Finally, 
purified human C2 was added in a limiting fashion (0.3 !g C2 to 5 ! 10
8 
cells), and cells 
were incubated at RT for 4 min, followed by a washing step.  EAC14b2a cells were 
resuspended in DGVB
++
 and utilized immediately.   
 
Convertase stabilization hemolysis assay   
NHS and the patient’s serum were heat inactivated at 56° C for 30 min and then 
diluted 1:5 in DGVB++.  EAC14b2a cells (50 !l) were mixed with 50 !l of DGVB++, 
NHS or patient’s serum.  Samples were incubated at 30° C to allow for decay of the 
convertase.  At the indicated time points, guinea pig serum, diluted 1:20 in 40 mM 
EDTA-GVB buffer, was added as a source of complement components.  Samples were 
" *+
incubated for 1 h at 37° C.  After centrifugation, hemolysis was assessed by measuring 
the absorbance of the supernatants at 414 nm.   
In other experiments the sera were first pre-treated with Protein G agarose to 
remove immunoglobulin (per the manufacturer’s instructions).  An equal volume of 
Protein G agarose slurry was added to the heat inactivated sera.  Samples were incubated 
on a rotator for 2 hrs at RT.  Following centrifugation at 1,000 x g for 5 min, the 
supernatants were collected.  Western blots were performed on the Protein G treated 
samples to visualize the efficiency of IgG removal.  The blots were probed with a donkey 
anti-human IgG HRP labeled antibody (Jackson Immunoresearch).  
 
C5 convertase stabilization assays   
Two approaches were used for C5 convertase assessment.  In the first approach, 
the C3 convertase was assembled as in the previous assays.  Following C3 convertase 
assembly, the patient’s IgG, a normal IgG control, patient’s serum, NHS, or buffer alone 
was added at 4°C for 5 min.  Next, cells were washed with DGVB
++
, centrifuged, and the 
pellets were resuspended in DGVB
++
.  Purified C3 was then added to each sample and 
incubated for 5 min at RT.  The cells were washed with DGVB++, resuspended in EDTA-
GVB and allowed to decay.  C3-depleted serum was diluted 1:20 in EDTA-GVB and 400 
!L was added to each tube as a source of terminal pathway components.  After a 1 hr 
incubation at 37° C, samples were centrifuged and absorbance of the supernatants 
determined at 414 nm.   
" *!
 The second strategy first required assembly of the C5 convertase on the EA cells.  
EAC14b cells were prepared first as described above.  C2 and C3 were then added 
simultaneously and incubated for 4 min at RT.  Following washing and centrifugation, 
the cells were resuspended in DGVB
++
 and treated with buffer alone, patient’s IgG, 
normal IgG, patient’s serum or NHS.  Samples were allowed to decay for various times.  
The degree of hemolysis was ascertained by addition of C3 depleted serum (see above).   
 
 
IgG purification   
The IgG fraction was purified from the patient’s serum and a control NHS using a 
Protein A column (Bio-Rad, Hercules, CA).  The column was equilibrated in 50 mM 
borate (pH 8.5) containing 150 mM NaCl.  The serum was applied to the column 
followed by extensive washing in the equilibration buffer.  Immunoglobulins were eluted 
with 200 mM glycine (pH 2.5) containing 500 mM NaCl.  The eluate fractions were 
neutralized by the addition of 1 M Tris (pH 9.0).  The IgG containing fractions were 
pooled and dialyzed against PBS overnight.  The IgG concentration was determined at an 
OD 280 nm using an absorbance coefficient of 1.35.  Purity of the purified IgG was 
assessed by SDS-PAGE under reducing and non-reducing conditions followed by 
Coomassie Blue staining.   
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RESULTS 
Patient description 
 The patient presented with Neisseria meningitides at 18 years of age.  He had no 
prior history of pyogenic infections or major illnesses.  At the time of hospitilization, a 
CH50 (complete complement titer) was performed and was below the limit of detection, 
and C3 antigen levels were also undetectable (Table 1).  Further testing determined that 
his FB, C2 and C4 levels were normal, while his C5 level was somewhat reduced (~50% 
of normal).  After a two-year follow-up the patient has remained healthy, while his C3 
levels are still undetectable. There was no family history of complement deficiency.   
 
Sequencing of patient’s C3 gene revealed no mutations  
Genomic DNA was sequenced using twenty-seven pairs of primers that 
encompassed all 41 exons and intron/exon borders of the C3 gene.  The sequences were 
aligned to the reference sequence available in GenBank with the accession number NG 
009557.  The sequence of the patient’s C3 gene was normal, with no truncations, splice 
site defects or amino acid substitutions identified.  The patient was homozygous for the 
slow form of C3 (Arg80) and carried the more common Pro at position 292.  
The sequencing results suggested that the C3 deficiency was not primary, but 
more likely related to accelerated turnover.  One possibility was that, while the C3 DNA 
was intact, the synthesis of the thioester bond, which is critical to C3 stability and 
function, was defective.  However, this hypothesis was less likely in view of the fact that 
the patient has normal levels of C4, a second thioester containing protein of the  
" *$
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complement system that is closely related to C3.  Another possibility was that the patient 
synthesized C3 normally, but it was prematurely cleared by, for example, an 
autoantibody to C3.   
To screen for the presence of an autoantibody to C3, ELISA was performed.  In 
comparison to NHS, there was no evidence of autoantibodies specific for C3 in the 
patient’s serum (not shown).  Therefore, we considered alternative mechanisms by which 
accelerated consumption of C3 could be occurring.  
 
Patient’s serum demonstrates C3 degradation products  
On multiple occasions, the standard clinical laboratory test for C3 antigen 
(nephelometry) detected no protein in this patient’s serum.  Thus, if C3 were present in 
the patient’s serum, it would be at very low levels.  Therefore, his serum was analyzed in 
a western blot at a 1:5 or 1:10 dilution in contrast to NHS which is routinely diluted 
1:500 or 1:1000 for western blots.  In the NHS sample, as expected, the intact " chain 
(110 kDa) and intact # chain (75 kDa) were observed.  In the patient’s serum, an intact 
C3 " chain was not present; however, there was evidence of C3 " chain degradation 
fragments ("41 and "27; 41 kDa and 27 kDa, respectively), as well as the intact 75 kDa # 
chain (Figure 3.1).  These bands correspond to those observed in the C3c control.   
C3c is normally generated from C3b through cofactor activity which is carried out 
by the serine protease FI in conjunction with a cofactor protein
18
.  In the serum, the major 
cofactor protein is FH, and on the cell surface the most widely expressed cofactor protein  
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is Membrane Cofactor Protein (MCP; CD46) whereas Complement Receptor 1 (CR1; 
CD35) has a more limited cellular distribution.  Upon binding to C3b, FI cleaves it in two 
locations to first generate iC3b, releasing C3f, and then at a third site to generate C3c and 
C3dg (Figure 3.2).  These results suggest that the patient’s liver synthesizes C3, but that it 
is undergoing accelerated activation to C3b, followed by the expected pathway to 
inactivate C3b, which generates C3c.  The patient therefore has a small amount of C3c in 
his serum which is derived from cofactor activity.  This protein is not observed in normal 
human serum as it is only generated in small amounts in normal individuals and is rapidly 
cleared.  
 
Normal C3 is degraded by the patient’s serum  
To assess if there was a factor in the patient’s serum capable of activating C3, 
serum-mixing experiments were performed (Figure 3.3).  At a 1:50 dilution of the 
patient’s serum, no C3 fragments are visualized (Figure 3.3, lane 8).  When NHS was 
mixed with the patient’s serum, C3 degradation fragments are visible (lanes 2, 3 and 4) 
consistent with iC3b.  This effect was dose dependent, as the evidence of consumption 
diminished as the amount of the patient’s serum added was decreased (compare lane 2 to 
lanes 3-7).  These results indicate that there is a factor in the patient’s serum capable of 
activating normal C3 to C3b.    
Additionally, the cleavage pattern is consistent with FH and FI mediated cleavage 
of newly generated C3b, based on the presence of the # chain and these two " chain 
fragments.  If the cleavage events were mediated by a non-specific protease, one would  
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expect to see bands of other molecular weights on the western blot; instead, the bands 
correspond to those generated by FI (cofactor activity).  The lack of cleavage from iC3b 
to C3c in these mixing experiments can be explained by the fact that there is no CR1 
present in serum.  CR1 is the predominant cofactor for FI in the further cleavage of iC3b 
to C3c.  In the patient, C3c may be seen because CR1 is expressed on his cells that 
mediate the final cleavage event by FI.    
Because native C3 is not susceptible to cofactor activity, this suggests that in this 
patient his C3 is being activated to C3b and then degraded by FI.  In the complement 
cascade, the activation of C3 to C3b is mediated by either the classical/lectin pathway 
(C4b2a) and alternative pathway (C3bBb) C3 convertases.   If either of these were to be 
stabilized, this could lead to consumption of C3.  For example, C3 nephritic factor (C3-
Neph) is an autoantibody to the alternative pathway C3 convertase that stabilizes this 
enzyme complex
19,20
.  Patients with C3-Neph present with low C3 and FB levels 
secondary to consumption by the stabilized AP C3 convertase.  However, no C3 nephritic 
factor was detected in this patient’s serum and the FB level was normal (Table 3.2).  
Therefore, we hypothesized that the classical pathway convertase was stabilized in this 
patient.  
 
The patient’s serum stabilizes the classical pathway C3 convertase  
To determine if the patient’s serum stabilizes the classical pathway C3 convertase, 
decay accelerating assays were performed using hemolysis of antibody sensitized sheep 
red blood cells (EA) as the readout.  In these assays, the convertase is assembled on EA 
" !++
and then allowed to decay for various times before addition of the terminal pathway 
complement components to produce hemolysis.  The convertase spontaneously decays 
(natural decay), resulting in less hemolysis at later time points.  If the convertase is 
stabilized, more hemolysis will be observed.   
The samples to which buffer alone was added demonstrate the expected natural 
decay of the convertase (Figure 3.4).  If the patient’s serum was added to the EA cells, 
there was no spontaneous decay of the C3 convertase.  The accelerated decay of the 
convertase (as compared to the buffer alone control) with exposure to NHS is due to 
C4BP in the NHS.   
Taken together, these results indicate that a factor in the patient’s serum is both 
capable of stabilizing the CP C3 convertase and of inhibiting decay by C4BP (normal in 
his serum- see Table 3.2).  If the assay time was extended up to eight hours, there was 
still no decay in the presence of the patient’s serum (not shown).   Additionally, if 
exogenous C4BP was added to the samples containing patient’s serum or normal serum, 
convertase decay was still not observed.  This confirms that the factor in the patient’s 
serum is inhibiting convertase decay by C4BP.   
 
IgG is the factor in the patient’s serum that is stabilizing the classical pathway C3 
convertase  
To assess if the convertase stabilizer/decay inhibitor was in the IgG fraction, we 
depleted the patient’s serum and NHS of IgG using Protein G beads (Figure 3.5).  
Untreated, the patient’s serum prevented decay of the convertase (as previously  
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demonstrated).  Following a single adsorption of the serum with protein G beads, the 
level of hemolysis was reduced by 50% (Figure 3.5A).  A second exposure to protein G 
beads reduced the hemolysis to 16%, comparable to that in the samples that received 
NHS.  This stepwise loss of stabilization paralleled the removal of IgG from the serum as 
determined by western blotting (Figure 3.5B).   
To further confirm this result, the IgG fractions purified from the patient’s serum 
and NHS were assessed for purity by SDS-PAGE followed by Coomassie blue staining 
(Figure 3.6).   The IgG samples were also analyzed in hemolysis assays (as described in 
Figure 3.3).  The IgG from the patient’s serum stabilized the classical pathway C3 
convertase while the IgG from NHS did not (Figure 3.7).  Thus, the factor leading to 
consumption of the C3 in this patient is likely an autoantibody to the classical pathway 
C3 convertase. 
 
C5 convertase stabilization assays 
 To determine whether the patient’s IgG was also capable of stabilizing the C5 
convertase, C5 convertase stabilization assays were performed.  These experiments were 
performed in two ways.  In the first approach, the C5 convertase was assembled on EA 
cells (EAC14b2a3b).  Following washing, the cells were treated with the patient’s serum 
or IgG, NHS or normal IgG, or buffer alone and then incubated for various times to allow 
for decay.  The results of these experiments (Figure 3.8) indicated that the IgG in the 
patient’s serum could not stabilize the preformed C5 convertase.  
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The second approach was a two-step assembly.  The C3 convertase was 
assembled, followed by addition of the patient’s or the normal samples, and then, C3 was 
added to form the C5 convertase.  This experiment design more closely mimics the in 
vivo formation of a C5 convertase.  The results of these experiments demonstrated that 
there was stabilization of the C5-convertase when the cells were treated with the patient’s 
serum, but not with the patient’s IgG.  In further experiments, purified IgG from the 
patient’s serum was added back to NHS that had been depleted of IgG by protein G.  
(Figure 3.9).  In these samples, there was no stabilization of the convertase.   
From this set of experiments, we conclude that the patient’s IgG cannot stabilize 
the preformed C5-convertase.  However, the results from the two-step C5-convertase 
assembly assays are unclear.  The patient’s whole serum stabilized the C5-convertase, but 
the patient’s purified IgG did not.  One possibility is that the C5 stabilizing activity did 
not co-purify with the C3-convertase stabilizer and was lost during purification.  The IgG 
was purified on a Protein A column, which does not bind human IgG3.  If the C5-
convertase stabilizer was a different isotype than the C3-convertase stabilizer, perhaps it 
was lost during the purification.   
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DISCUSSION 
Here we describe a patient who presented with a life-threatening Neisseria 
meningitides sepsis and meningitis.  Clinical laboratory tests revealed an undetectable 
whole complement titer secondary to an absence of C3.  Genomic sequencing of the 
patient’s C3 gene did not identify a deletion, mutation or splice site defect.  Western blot  
analysis established that there was a very low level of degraded C3 antigenic fragments in 
the patient’s serum, suggesting that C3 was being synthesized.  If the patient’s serum was 
mixed with NHS, activation of normal C3 was observed.  The factor cleaving C3 was 
identified as the classical/lectin pathway C3 convertase.  This observation was accounted 
for by identification of an autoantibody that stabilized the CP/LP C3 convertase.   
  The development of an autoantibody to the AP C3 convertase (C3-Neph) was 
described in the 1970’s
20,21
.  It was usually found in association with a membranous 
glomerulonephritis.  In particular, it was described with Type II MPGN (Dense Deposit 
Disease), partial lipodystrophy and SLE.  There have only been a few reports over the 
past 30 years of this phenomenon
19
.   
There have also been a rare reports of a C4 nephritic factor (C4-Neph), an 
autoantibody that stabilizes the classical/lectin pathway C3 convertase8,10,16.  In the 
largest series in the literature, about 100 patients with membranous glomerulonephritis 
and C3 levels less than 40% of normal were screened for C3 and C4 nephritic factors
16
.  
Of the 37 patients who met these criteria, about one-third each had C3-Neph, C4-Neph or 
both.  In another study of lupus patients, two of 16 screened were shown to have C4-
" !!+
Neph
10
.  The complement levels reported in the MPGN patients with C4-Neph and the 
patient described here are similar in that C3 was low and C4 and FB levels were normal.  
However, our patient had no renal abnormalities at presentation or during a two-year 
follow up.   
 Interestingly, the patient described here had been previously healthy with no 
history of unusual infections until he developed the Neisseria infection at the age of 18, 
suggesting that the stabilizing antibody was recently acquired.  One possibility to explain 
the newly acquired antibody is that, during the course of an infection, the adaptive 
immune system mistakenly recognized a neoepitope on the convertase.  However, it is 
known that, like the alternative pathway, the classical pathway also undergoes a 
continuous low-grade tick-over, secondary to the low level, spontaneous activation of 
C1
22
.  This classical pathway tick-over indicates that a C3 convertase is continuously 
being formed in small amounts in blood.  Why this patient generated a B cell response to 
this autoantigen is unknown.   
 This patient’s presentation and clinical course to date seems to be unique.  We 
could find no case in the literature in which a patient with C4-Neph came to medical 
attention because of a Neisserial infection.  As noted, C4-Neph has been described with 
MPGN in three reports8,9,16 and with two SLE patients in another10.  We could find no 
reports on such patients since 1994.  This patient does not have glomerulonephritis or 
SLE as the reported patients with C4-Neph did.  It will be of interest to monitor this 
patient’s clinical case to see if it results in glomerular disease in the future.  
" !!!
The patient’s C5 level was about 50% of normal and of course, he could not 
generate a C5 convertase.  It is still unclear whether his low C5 is induced by a stabilized 
C5 convertase or an increase in C5 cleavage by the C3 convertase.  The absence of 
properdin or any component of the membrane attack complex (C5-9) predisposes to 
Neisserial infections
7
.  In our patient, the lack of C3 was presumably why he developed 
this infection.   
 This antibody could be a useful tool.  The structural analysis of the classical 
pathway C3 convertase has been hampered by the highly transient nature of the complex.  
Having an antibody that stabilizes this complex could facilitate such structural studies 
and provide further insight into the assembly and function of the classical/lectin pathway 
C3 and C5 convertases.  Also, this type of a reagent could be utilized to selectively 
deplete C3 in vivo.   
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CHAPTER 4 
Concluding remarks and future directions 
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Introduction 
The complement system is an essential branch of the innate immune system1.  It 
serves as a first line of defense against invading pathogens as well as having an important 
role in debris clearance.  Through three protein cascades, the classical, lectin and 
alternative ptathways, it recognizes danger associated molecular patterns, and leads to the 
deposition of the central component, C3, on a target
2,3
.  A properly functioning 
complement system requires tight regulation
4
.  Because the complement system can be 
quickly amplified through the alternative pathway’s amplification loop, mechanisms are 
in place to prevent inappropriate complement deposition on host cells and tissues.  When 
this homeostatic regulation is disrupted, pathogenic states usually develop5.  Some 
examples of these include paroxysmal nocturnal hemoglobinuria (PNH), atypical 
hemolytic uremic syndrome (aHUS), dense deposit disease (DDD) and age-related 
macular degeneration (AMD)
6
.  The focus of this dissertation has been to examine 
complement dysregulation at the step of C3 activation in two human disease states. 
 
Summary and conclusions: aHUS 
The first aim was to study the role of C3 mutations in aHUS.  In this disease, 
patients present with microangiopathic hemolytic anemia, thrombocytopenia and acute 
renal failure.  Previous studies have shown that mutations in the complement regulatory 
genes FH, FI and MCP predispose to development of the disease
7–9
.  Here, I described 
mutations in the central component, C3, that were identified in aHUS patients.   
" !!(
 Sequencing of the C3 gene was carried out in three cohorts of aHUS patients.  
The mutations were heterozygous in all cases.  To study the mutant C3 proteins, I 
produced them recombinantly in mammalian cells and then characterized their interaction 
with the regulatory proteins MCP, FH and CR1, as well as the activating component FB.  
Utilizing ELISA, a fluid phase cofactor assay and SPR analysis, in the majority of the 
cases (13/16) the mutation caused defective interactions with one or more regulatory 
protein(s).  This decreased binding to an inhibitor leads to a secondary gain of function.  
One mutation, R139W, also had an increased ability to bind to Factor B, resulting in a 
longer-lived C3 convertase. In endothelial cell assays, an increase in C3 deposition was 
observed with serum containing R139W C3 compared to WT C3.    
These experiments represent the first examples of mutations in C3 that predispose 
to aHUS.  Together with the studies of the mutations in the complement regulatory genes, 
abnormalities in the complement system have now been strongly linked to development 
of aHUS.  The identification and characterization of these mutations has pointed to 
inhibitors of the complement system as a therapeutic target for aHUS patients
7,10
.  It has 
also focused attention on the critical nature of complement regulation on the endothelial 
cells of the kidney microvasculature.  
 
Model: aHUS 
A model aHUS development is shown in Figure 4.1.  There is low-level activation 
of the AP at all times, through spontaneous hydrolysis of C3 (~1-2% per hour)
5
.  In a 
normal kidney, this activation in the microvasculature is held in check through the action 
" !!)
of regulatory proteins.  Each endothelial cell has approximately 1.5 million copies of 
CD59 (MAC inhibitor), 400,000 copies of MCP and 200,000 copies of DAF (personal 
communication, Anna Richards).  If C3b is deposited on a cell surface, it is inactivated to 
iC3b by MCP or FH and FI
9
.  However, in the glomerulus of a patient with a mutation in 
a complement gene (Figure 1, bottom panel), the inhibition is less efficient
9,11
.  Upon a 
triggering event causing endothelial cell stress or damage, the complement system is 
further activated.  If the amplification loop is not regulated normally, excessive 
complement activation leads to undesirable deposition and damage to endothelial cells.  
Adhesion molecules are upregulated on the endothelial cells, probably by C3a and C5a.  
This receptor engagement also recruits inflammatory leukocytes.  Endothelial cell 
swelling or detachment may lead to exposure of the subendothelial matrix, further 
inducing a prothrombotic state.  The result is formation of a fibrin and platelet rich clot in 
the microvasculature.  
 
Future directions: aHUS 
Genetic studies are ongoing in aHUS patients.  Approximately 70% of patients 
have a mutation in a complement gene or autoantibodies to FH (<10%)10,12.  However, 20 
to 30% of patients still have no genetic defect identified.  It will be of interest to 
determine if these patients have mutations in other complement- or coagulation-related 
genes.  Also, while a defect in the complement system is a predisposing factor to aHUS 
development, the mechanisms linking this to clot formation have not been defined.   
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It is clear that there is cross talk between complement and coagulation.  Studies 
have shown that C5a can be generated in the absence of C3, and have implicated the role 
of thrombin in this event13.  Another report revealed that C5a is able to induce tissue 
factor expression on endothelial cells
14
.  Tissue factor leads to the generation of 
thrombin, which is the key factor converting fibrinogen to fibrin
15
.  The formation of a 
fibrin clot causes ischemic events in the renal glomerulus in aHUS.  Finally, mutations in 
thrombomodulin have also been described in aHUS
16
.  Thrombomodulin is a membrane 
bound anticoagulant protein that down-regulates thrombin generation and has recently 
been shown to inhibit the AP by enhancing FI mediated inactivation of C3b.   
 Further studies of the interaction between the complement system and the 
coagulation cascade will help to elucidate mechanisms of disease development, as well as 
provide insights into the cross-talk between these two systems that are critical 
components of immunity and homeostasis.   
 
Summary and conclusions: Secondary C3 deficiency 
 The second aim of this work focused on a case of C3 deficiency.  This patient 
presented at the age of 18 with a life-threatening infection with Neisseria meningitides.  
His history was notable in that he had no prior history of serious pyogenic infection or 
other major illnesses.  Clinical laboratory testing revealed an undetectable whole 
complement titer and absence of the C3 antigen.  I sequenced his DNA and identified no 
abnormalities in the C3 gene.  Western blot analysis of his serum revealed trace C3 
fragments.  Importantly, in mixing experiments, his serum activated the C3 in normal 
" !#!
human serum.  Hemolytic assays indicated that this was due to stabilization of the 
classical pathway C3 convertase and that the lytic activity was in the IgG fraction.  Thus, 
we concluded that this patient had an autoantibody to the classical pathway C3 
convertase.  This stabilized convertase led to complete consumption of his C3, inducing a 
secondary C3 deficiency.  A few cases of secondary C3 deficiency such as in our patient 
were previously described as C4 nephritic factors
17–19
.  However, there have been no 
reports of this phenomenon over the past nearly twenty years.  This autoantibody was so-
named due to the presence of glomerulonephritis in all of these patients.  However, this 
patient did not have renal disease at presentation or after a two year of follow-up.      
The generation of C3b by the classical pathway C3 convertase is usually regulated 
by three mechanisms.  The first is the natural decay of the convertase, with a t1/2 of two to 
three minutes.  The second mechanism is decay accelerating activity (facilitated decay), 
which is provided by DAF on cells and C4BP in the fluid phase.  The autoantibody in this 
patient prevents natural decay and blocks decay accelerating activity by the two 
regulatory proteins. The third mechanism is cofactor activity.  The inability of MCP or 
C4BP to bind to the CP C3 convertase bound by the autoantibody prevents them from 
serving as a cofactor protein for cleavage of C4b by FI.  The outcome therefore of this 
pathologic situation is massive consumption of C3 and inappropriate deposition of C3 
fragments.  Typically, in the limited literature, this leads to a glomerular disease
20
.  This 
patient does not have glomerulonephritis but rather presented with a Neisseria infection 
which is more commonly associated with a complete deficiency in properdin or one of 
the terminal pathway components (C5-C9)
21
.    
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Finally, the study of this C3 deficient patient supports the concept of continuous 
classical pathway turnover.  A recent study demonstrated that C1 undergoes spontaneous 
activation leading to cleavage of C4 and C222.  In this patient, the spontaneous turnover 
would provide a constant supply of antigen (convertase) for the autoantibody to bind and 
stabilize.   
 
Future directions: C3 deficiency 
 Further studies of the binding interaction of the antibody with the classical 
pathway C3 convertase are ongoing.  It is most likely that the antibody is directed 
towards a neoepitope formed when the two subunits (C4b and C2a) are in a C3 
convertase.  The patient also has half normal levels of C5, so perhaps he is also turning 
over this component.  Formation of a C5 convertase is inefficient in the fluid phase, but 
the C3 convertase can also cleave C5, although with less efficiency than it cleaves C3
23
.  
Perhaps the stabilized convertase is now able to cleave more C5, in the setting of its 
longer half-life and low levels of its preferred substrate, C3.  Purification of this antibody 
may prove to be useful for studies of the classical pathway convertase, which has not 
been crystallized due to its short half-life.  Finally, the ability to selectively deplete C3 in 
vivo in order to prevent undesired complement deposition could also be possible with this 
autoantibody. 
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Final thoughts 
 The role of the complement system in health and disease is still being elucidated.  
Several disorders have been linked to poorly controlled complement activation, including 
aHUS, DDD, AMD, PNH and forms of glomerulonephritis.  It is clear that a fine balance 
must be maintained between activation and regulation.  The two cases presented here 
provide an interesting contrast relative to complement regulation.  In the first case, there 
is a relative defect in regulation (haploinsufficiency) of the mutated C3b once it is 
deposited on self-cells.  This lack of appropriate regulation leads to endothelial cell 
damage and clot formation.  In the second case, regulation of the convertase is blocked 
by the autoantibody.  Therefore, all of the C3 is turned over, resulting in C3 deficiency.  
Interestingly, in many cases of secondary C3 deficiency such as this one, the patient 
presents with renal disease.  In both cases then, there is excessive complement deposition 
leading to tissue damage in the kidney.  Additional analysis of the patient may uncover 
why this patient has not developed kidney disease.  Defining the specific mechanisms 
that maintain homeostasis of the complement system will further our understanding of 
disease states and lead to improved therapy for these conditions.  
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Endothelial cell assays$
Conditionally immortalized GEnC 
10, 20
 (passage 29-35) and third passage primary HUVEC were used for 
this study. Detailed of culturing conditions are given in the Supplement (Patients and Methods). Briefly, 
GEnC and HUVEC, either resting or stimulated with TNF$/IFN%, were exposed to normal human sera 
(NHS) from 50 donors or R139W sera or FH-depleted (FH-dpl) serum. Alternatively, blocking anti-FH 
(Ox24 
21
) monoclonal antibody was added to these sera or anti-MCP (GB24 
22
). Also R139W sera were 
supplemented with different concentrations of purified FH (Comptech, Tylor TX). Released C3a, C5a and 
sC5b9 were measured in the supernatant using specific ELISAs (Quidel, San Diego, CA). Cells were 
incubated with a mouse anti-human C3c mAb (Quidel, San Diego, CA), followed by a secondary anti-
mouse IgG-PE or an anti-Tissue Factor-PE antibody (BD Pharmingen) and analyzed by flow cytometry as 
described in the Supplement (Patients and Methods). 
;#.&'?5*-*+$%P$(7&49.+5&*$$
PI@" L!$*W" 9J/-D/" =$" [-8" 7105J.@5" E109" /I@" [G45" /N7@" ?WPA" =$" 74-89G5" -8"
5@8.1GC@5" &T" PI@" @K71@88G0D" 4@R@4" 0E" /I@" 74-89G58" [-8" .097-1@5" -E/@1" 9J4/G74@"
/1-D8G@D/"/1-D8E@./G0D8"J8GDO"\G70E@./-9GD@T"PI@"74-89G5"[-8"GD/105J.@5"GD/0"=2h"
.@448" RG-" 8/-C4@" /1-D8E@./G0D" J8GDO" 8@4@./G0D" [G/I" Y%!)T" PI@" .0D8/1J./8" [@1@"
8@]J@D.@5" GD" /I@G1" @D/G1@/N" /0" .0DEG19" /I-/" D0" -55G/G0D-4" 9J/-/G0D8" I-5" C@@D"
GD/105J.@5T" PI@" 8ND/I@8G8" 0E" =$" [-8" -88@88@5" CN" -" 8-D5[G.I" `\>X;<" J8GDO"
G990CG4G_@5" -D/GZIJ9-D"=$" -D/GC05N" E01" .-7/J1@" -D5"CG0/GDN4-/@5" -D/GZIJ9-D"=$<"
E0440[@5" CN" 8/1@7/-RG5GDZ2018@1-5G8I" F@10KN5-8@" ?2LFA" ?;9@18I-9<"
3J.SGDOI-98IG1@<" Y3A" E01" 5@/@./G0DT" PI@" @K71@88G0D" 4@R@48" [@1@" 8G9G4-1" C@/[@@D"
WP" -D5" 9J/-D/" 74-89G58T" XJ7@1D-/-D/8" 5@1GR@5" E109" 8/-C4@" /1-D8E@./@5" .@448"
.0D/-GDGDO" 1@.09CGD-D/"WP" -D5" L!$*WZ=$" -8"[@44" -8" 8J7@1D-/-D/8" 0E" /I@"90.SZ
" !%+
/1-D8E019@5".@448" ?XM+A<"[@1@"J8@5" /0"7J1GEN"=$"CN"G0D" @K.I-DO@".I109-/0O1-7IN"
J8GDO":`;`"X@7I-108@"?Y`"2@-4/I.-1@A"-D5"@4J/@5"[G/I"+T#B"M-=4T""
"
Surface plasmon resonance 
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Genetic analysis  
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In summary, we describe the genotype-phenotype and structure-function relationships for a frequent direct 
gain-of-function mutation in C3. The number of patients and healthy carriers with the R139W form of C3 
on different genetic backgrounds indicates that this mutation, particularly if associated with an at-risk FH 
and/or MCP haplotypes, becomes pathogenic in association with an endothelium damaging event. 
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